Chimerenomic macromolecular RNA enzymes for modulation of biological functions and treatment of disease

Chimerenomic RNA enzymes address the inadequacies of current therapies by degrading dysfunctional RNAs, restoring cellular function, and enabling early diagnosis and targeted treatment for Alzheimer's and Parkinson's disease.

WO2026240879A1PCT designated stage Publication Date: 2026-11-19AMERICAN ACADEMY OF PRIMARY CARE RESEARCH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/020896
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-03-26
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current therapies for neurodegenerative disorders like Alzheimer's and Parkinson's disease are inadequate due to a lack of effective interventions targeting the malfunctioning of mRNAs, tRNAs, and rRNAs, and the complexity of protein misfolding and aggregation mechanisms.

Method used

Development of chimerenomic macromolecular RNA enzymes (NTinti) that degrade dysfunctional genetic code-based RNAs through a non-natural, chemically created hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complex, enabling the production of large RNA enzymes capable of regulating protein synthesis and mitigating protein misfolding.

Benefits of technology

The NTinti RNA enzymes provide a comprehensive treatment strategy by specifically degrading malfunctioning RNAs, restoring normal cellular function, and offering early diagnostic tools for neurodegenerative diseases, potentially leading to improved patient outcomes and tailored treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026020896_19112026_PF_FP_ABST
    Figure US2026020896_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Macromolecular, non-genetic code-based NTinti RNA enzymes are prepared using non-natural NADH-glutamate dehydrogenase (GDH) redox cycle isoenzymes that are assembled into a hexameric enzyme complexes. The macromolecular NTinti RNA enzymes degrade superfluous, mutated, dysfunctional total RNA thereby reprogramming metabolic reactions and biological processes, restoring normal cellular functions mitigating the detrimental effect of protein misfolding and aggregation in health and disease.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONCHIMERENOMIC MACROMOLECULAR RNA ENZYMES FOR MODULATION OF BIOLOGICAL FUNCTIONS AND TREATMENT OF DISEASE REFERENCE TO A SEQUENCE LISTING

[0001] This application contains a Sequence Listing XML, which has been submitted electronically and is hereby incorporated by reference in its entirety. Said Sequence Listing XML, created on August 15, 2025, is named 170364_2 - Sequence Listing.xml and is 16,000 bytes in size.BACKGROUND

[0002] This disclosure pertains to (production of chimerenomic) macromolecular RNA enzymes (called NTinti), their method of synthesis, and uses thereof in modulation of biological functions and treatment of diseases such as Alzheimer’s Disease and Parkinson’s Disease.

[0003] Protein misfolding not only contributes to the distinct characteristics of most human health disorders but also facilitates crosstalk between different pathologies. This highlights the potential for shared therapeutic strategies targeting the underlying mechanisms of mutated, dysfunctional, and misfolded proteins. Understanding these interactions is crucial for developing comprehensive treatment approaches for patients suffering from health disorders related to proteinopathies. Understanding these interactions is also crucial for developing targeted therapeutic strategies. While the roles of proteins and ribosomes, rRNA, tRNA, and mRNA in the protein synthesis process have been acknowledged, a definitive genetic code-based RNA solution for neurodegenerative disorders remains elusive.

[0004] Alzheimer’s dementia and Parkinson’s disease, in particular, are complex neurodegenerative disorders that have defied efficacious therapies. The root causes of the two disorders are the malfunctioning of superfluous / mutated mRNAs, tRNAs, rRNAs, and proteins [ Okea and Osuji, 2024], Despite extensive research efforts since Dr. Alois Alzheimer’s initial observations in 1906, advancements in understanding and treating Alzheimer's disease remain limited. There is a persistent focus on combating amyloid beta (A ) protein clumps and neurofibrillary tangles (NFTs), but effective interventions have proven elusive [Okea and Osuji, 2024], In Parkinson's disease (PD), disruptions in mRNA processing have been linked to the small ribosomal subunit protein uS13. These malfunctions can result in flawed protein- 1 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONsynthesis, contributing to neurodegeneration [Okea and Osuji, 2024], Research suggests that alterations in the translation machinery may play a crucial role in the progression of PD, like in Alzheimer’s disease. Ongoing studies continue to analyze these pathological markers and to attempt to elucidate the interplay between mechanisms, highlighting the complexity of the illnesses. As scientists seek innovative approaches, it becomes increasingly clear that a broader perspective may be needed to unravel the mechanisms of Alzheimer's and PD and develop viable treatments.

[0005] What is needed, therefore, is a comprehensive treatment strategy that focuses on enhancing the regulation of RNA molecules involved in protein synthesis, leading to specific degradation of malfunctional mRNAs, rRNAs, tRNAs, and the like, restoration of normal cellular function, and mitigation of the detrimental effects of protein misfolding and aggregation.SUMMARY

[0006] The present disclosure relates generally to cell and tissue-specific, non-genetic code-based macromolecular chimerenomic RNA enzymes, NTinti, that are capable of degrading homologous superfluous and dysfunctional genetic code-based RNAs (rRNAs, mRNAs, tRNAs, and the like) thus preventing them from entering protein translation.

[0007] The macromolecular NTinti RNA enzymes are catalyzed using non-natural, chemically created hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes. These complexes facilitate the production of large quantities of the NTinti RNA enzymes through unique processes described herein. The NTinti RNA enzymes are remarkably large, with some containing over 10.5 billion nucleotide bases. This size makes them approximately three times larger than the entire human genome, which consists of 3.2 billion base pairs, and 100 times larger than the human brain transcriptome. The NTinti RNA enzymes may be produced in both the deamination and amination reaction directions of the hexameric NADH-GDH redox cycle isoenzyme complexes. A unique synthesis technique uses any biological cell extract to produce the non-natural, chemically created NADH-GDH hexameric redox cycle isoenzyme complexes, which are then employed in a further unique process to produce NTinti RNA enzymes.

[0008] The NTinti RNA enzymes described herein possess transformative capacities for therapeutic applications across various fields, including but not limited to neurology,- 2 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONendocrinology, nephrology, pulmonology, gastrointestinal, oncology, hematology, cardiovascular, clinical and addiction medicine, pharmacology, and cell biology including aging reversal.BRIEF DESCRIPTION OF THE DRAWINGS

[0009] FIG. 1 shows a schematic and flow chart of preferred embodiments of steps involved in purifying hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes and using the complexes in the synthesis of exemplary chimerenomic macromolecular RNA enzymes.

[0010] FIG. 2 shows an image comparing the GDH Isoenzyme Fingerprint for Control A (at Confluency) and Control B (at 2 days post Confluency).DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0011] The present disclosure relates to macromolecular, non-genetic code-based RNA enzymes produced to modulate biological functions in health and in disease. The production process involving the creation of the catalyst NADH-glutamate dehydrogenase (GDH) redox cycle isoenzymes that are assembled into a hexameric enzyme complex.

[0012] FIG. 1 shows a schematic and flow chart of the chimerenomic pump. Projection of the outcomes of the integrated free solution isoelectric focusing, and polyacrylamide gel electrophoretic purification of NADH-glutamate dehydrogenase redox cycle hexameric isoenzymes, and chigramming of kilogram yields of plus-chimerenomic RNA in the amination direction and minus-chimerenomic RNA in the deamination direction in an infinitely reciprocating chigramming cycles. The chimeres chigrammed by the acidic isoenzymes (pl 5.1) in the amination direction (lane A), and deamination direction (lane E); mildly acidic isoenzymes (pl 6.3) in the amination direction (lane B), and deamination direction (lane F); neutral isoenzymes (pl 7.2) in the amination direction (lane C), and deamination direction (lane G); mildly alkaline isoenzymes (pl 8.0) in the amination direction (lane D), and deamination direction (lane H) were used for cDNA synthesis. The cDNAs were digested with taq 1 restriction enzyme, the fragments were amplified by Double Differential PCR method, and the products were fractionated on sequencing polyacrylamide gel. Note the differential yields of product chimeras by GDH Shiff bases according to the pl values of the GDH isoenzymes, and amination versus deamination in the chigrammer [Osuji et al., 2021],- 3 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATION

[0013] Preferred embodiments described herein are derived from a field of study, referred to as chimerenomics or chimerenomic sciences, which focus on synthesizing and producing a unique NTinti RNA enzymes designed to target the underlying molecular mechanisms of several human health disorders. By enhancing the regulation of RNA molecules involved in protein synthesis, these enzymes specifically degrade malfunctional mRNAs, rRNAs, tRNAs, and the like, restoring normal cellular function and mitigating the detrimental effects of protein misfolding and aggregation.

[0014] Before the advent of chimerenomic sciences, scientists derived all functional RNA molecules from the genetic code through transcription from DNA, producing various forms of RNA such as mRNA, rRNA, tRNA, siRNA, and others. Chimerenomic sciences, as described herein, has revolutionized this process by enabling the synthesis of RNA without relying on any template including the genetic code of DNA or existing RNA. This breakthrough allows scientists to create specialized RNAs solely by polymerization of ribo-NTPs, independent of any genes. This innovation marks a significant leap forward, as scientists can now synthesize entirely man-made RNA macromolecular entities with full biological functions independent of DNA or any template.

[0015] In nature, human cells do not produce chimerenomic NTinti RNA enzymes described herein in vivo due to various cellular inhibitions. However, the inventors have made history by developing a proprietary technique that artificially produces NTinti RNA enzymes with complete biological functions. Preferred embodiments of these enzymes referred to as chimerenomic NTinti, and are also described herein as chimerenomic macromolecular RNA enzymes.

[0016] Chimerenomic NTinti macromolecular RNA operates as a standalone enzyme, setting it apart from genetic code-based RNAs like mRNA, tRNA, rRNA, and others. In this context, these genetic code-based RNAs serve as substrates for chimerenomic RNA. Chimerenomic RNA enzymes degrade genetic-code based RNA by a chemical mechanism different from those of siRNA and microRNA [Osuji, et al, 2019] *****

[0017] This disclosure focuses on the processes and tools necessary to synthesize, produce, quantify, and characterize these novel chimerenomic NTinti RNA macromolecular enzymes for biological modulation and disease treatment. In preferred embodiments, NTinti nongenetic code-based RNA enzyme is produced to modulate biological functions in health- 4 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONand in disease, including treatment of diseases, prevention of diseases, diagnosis of diseases, and use in biomedical research.

[0018] Certain new terminologies in the life sciences are used herein to describe the discovery of template-independent RNA processes that control the survival of cells and organisms other than genes. The building blocks of this life regulatory system are made up of a unique type of RNA that are not coded nor synthesized through the genetic code. These template-independent RNAs are called chimerenomic RNAs.

[0019] The term chimerenomics refers to the study of everything (NTintis, chigramming, GDH-chimmerization, chimere, etc.) about chimerenomic RNAs. Chimerenomics confers molecular chemistry pluripotency and totipotency to all cells and tissues. Chimerenomics are the processes by which whole organisms, cells and tissues differentiate, develop and grow by chigramming chimerenomic RNAs that interact with the changing physicochemical internal and external environmental conditions thereby reprogramming and optimizing those metabolic reactions that assure the continued survival of the organism.

[0020] The term chimere refers to the minimum length of nucleotide sequence that can degrade homologous mRNA and other genetic code-based RNAs. Chimere is the active segment of NTinti. It can range from 5 nucleotides to many billions of nucleotides.

[0021] The term NTinti refers to a preferred embodiment of the chimerenomic RNA molecule chigrammed (synthesized) by NADH-glutamate dehydrogenase hexameric redox cycle isoenzymes (GDH) in response to a specific environmental change. NTinti can be cell or tissue specific. One NTinti has one or more chimeres.

[0022] The term chigramming refers to the process of synthesis of chimeras and NTintis by NADH-GDH redox cycle isoenzyme. It is a spontaneous process. It is the conversion of the electromagnetic changes in the environmental conditions of cells, tissues, whole organisms to the nucleotide sequences of chimerenomic RNAs.

[0023] The term GDH-Chimerization refers to the formation of chemical Schiff base of GDH isoenzymes in response to a new environment leading to new hexameric isoenzyme complexes. This is the initiation process for chigramming.- 5 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATION

[0024] The term functional chimerenomics refers to the study of the biological functions of chimere and NTinti.

[0025] The term differential chimerenomics refers to the comparison study of the chimeres and NTintis from same or different tissues under various environmental conditions.

[0026] Additional terminologies include the term clinical chimerenomics, which refers to the application of chimerenomics to clinical studies, and chimerenomic medicine, which refers to the application of chimerenomics to primary care in the prevention and treatment of human disorders, diseases and wellness conditions in humans. Similar terms may include chimerenomic chemistry, chimerenomic physiology, molecular chimerenomics, chimerenomic biology, chimerenomic pharmacology etc.

[0027] Preferred embodiments described herein relate the use of non-natural, chemically created hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes to produce the unique NTinti RNA enzymes through a process referred to herein as chigramming. Chigramming allows for the creation of cell and tissue-specific NTinti RNA enzymes made up of chimeras. Chimeras are RNA nucleotide sequences of a minimum length that can degrade homologous mRNA and other genetic code-based RNAs and are the active segments in the NTinti RNA enzymes. In preferred examples, when the hexameric GDH redox cycle isoenzyme complexes are derived from human astrocyte cell extracts at confluency, chigramming yields macromolecular RNA enzymes composed of about 63 million chimeras. At post-confluency, the hexameric GDH redox cycle isoenzymes from human astrocytes produces macromolecular RNA enzymes made up of approximately 71 million chimeras, with each chimere being 150 nucleotides long. Beyond astrocytes, the techniques described herein allow for the utilization of any biological cell extract to produce cell and tissue-specific macromolecular RNA enzymes.

[0028] Additional preferred embodiments described herein relate to the preparation of non-natural, chemically created hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes using embodiments of an isoelectric focusing cell that arranges the hexameric GDH redox cycle isoenzymes according to the electrochemical gradient of their isoelectric point (pl) values, a polyacrylamide gel electrophoresis cell that concentrates all the GDH hexameric isoenzymes, and a whole gel eluter. The reacting concentrations of the preferred GDH hexameric isoenzymes are optimized with respect to their respective isoelectric- 6 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONpoint (pl) values because they are also substrates in the Schiff base reaction, which is an important step in the chimerenomic macromolecular RNA enzyme production, or chigramming.

[0029] As used herein, the term non-natural means that the hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes do not occur naturally and are prepared using the steps described. This is in contrast with a native or natural protein, which has a biological source and may be isolated and purified.

[0030] Although the substrate specificities of glutamate dehydrogenase redox cycle hexameric isoenzymes have been identified and optimized, industrial productions and distributions of chimerenomic NTinti RNA enzymes are needed to support the research and clinical technologies. No one has sought to optimize the Schiff base reaction chemistry, and not for the chimerenomic NTinti RNA production using proprietary GDH redox cycle hexameric isoenzyme complexes.

[0031] Chimerenomic RNA is a type of RNA enzyme not based on the genetic code *********** hat all cells produce in response to both internal and external signals to correct and eliminate superfluous genetic code-based total RNAs. In this way, it gets rid of malfunctioning mRNAs, rRNAs, tRNAs, and others before they have the chance to create proteins. As a result, the body ensures that only functional mRNAs, rRNAs, tRNAs, and similar molecules reach their target for protein synthesis. The efficiency of chimerenomic RNA enzymes is influenced by age, internal and external environmental factors, that can lead to a cascade of genetic code errors and cellular dysfunction. In both ideal and adverse environments, the synthesis of chimerenomic RNA enzymes plays a vital role in maintaining this balance. By continuously producing these enzymes, cells can effectively counteract the potential disruptions caused by harmful stimuli.

[0032] The synthesized chimerenomic NTinti RNA enzymes described herein hold significant promise for the early diagnosis of both Alzheimer's Disease (AD) and Parkinson's Disease (PD), as well as other diseases or disorders that result from superfluous or malfunctioning mRNAs. Their unique properties can be leveraged in at least two exemplary ways. One is serum mRNA Assays. The homologous sequences of the chimerenomic RNA enzymes can be utilized as probes in serum mRNA assays. By targeting specific malfunctional mRNAs associated with AD and PD, these probes can help identify the presence of these- 7 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONdiseased mRNAs in patients' cells and serum many years before the manifestation of disease symptoms. This approach will allow for a non-invasive method of screening that could facilitate early detection, enabling timely intervention and management of these neurodegenerative conditions. The second is a functional chimerenomic search engine, which involves isolating and sequencing individual cell specific chimerenomic RNA. By employing the functional chimerenomic search engine, research scientists can analyze the sequences for abnormalities linked to AD and PD. This method not only aids in identifying specific genetic markers associated with the diseases but also enhances understanding of the underlying molecular mechanisms at play.

[0033] These diagnostic strategies could revolutionize the way the early detection of Alzheimer's and Parkinson's diseases is approached. By enabling earlier and more accurate diagnoses, patient outcomes can be improved and treatment plans can be tailored more effectively, ultimately enhancing the quality of life for those affected by these challenging disorders.

[0034] The macromolecular chimerenomic RNA enzymes also represent promising therapeutic remedies aimed at addressing Alzheimer's Disease (AD) and Parkinson's Disease (PD). Given their demonstrated ability to target and correct malfunctioning mRNAs associated with these neurodegenerative conditions, these agents can be utilized in suitable pharmaceutical compositions and other treatments.

[0035] Preferred embodiments relate to a pharmaceutical composition for administration to a subject including a therapeutically effective amount of a composition comprising chimerenomic NTinti RNA enzymes and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabilizer. A “therapeutically effective amount” means a nontoxic but sufficient amount of the composition to produce a positive biological effect on a disease or condition being treated. The amount that is “effective” will vary from subject to subject, depending on the age and general condition of the individual, the particular concentration and composition being administered, and the like. Thus, it is not always possible to specify an exact effective amount. However, an appropriate effective amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation. The actual amount, rate and time-course of administration will depend on the nature and severity of the disease being treated. Prescription of treatment is within the responsibility of general practitioners and other medical doctors. Furthermore, the effective amount is the concentration - 8 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONthat is within a range sufficient to permit ready application of the formulation so as to deliver an amount of the drug that is within a therapeutically effective range. The pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabilizer should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, such as cutaneous, subcutaneous, or intravenous injection, or by dry powder inhaler. In pharmaceutical compositions for intravenous, cutaneous or subcutaneous injection, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has a suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as sodium chloride solution, Ringer’s solution, or lactated Ringer’s solution. Preservatives, stabilizers, buffers, antioxidants and / or other additives may be included as required.

[0036] Preferred embodiments described herein include a method for synthesizing chimerenomic NTinti RNA enzymes, comprising preparing non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes. The non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes are preferably prepared through a method comprising the steps of extracting NADH-glutamate dehydrogenase (GDH) enzymes from cells using an extraction buffer, wherein the extraction buffer comprises RNase and DNase for the degradation of genetic code-based RNA and DNA, to prepare linearized and monomerized subunits of NADH-glutamate dehydrogenase (GDH) enzymes, followed by using isoelectric focusing to separate and arrange the linearized and monomerized subunits into hexamers of NADH-glutamate dehydrogenase (GDH) enzymes according to electrochemical gradient of pl values, followed by using polyacrylamide gel electrophoresis to concentrate redox cycle hexameric NADH-glutamate dehydrogenase (GDH) enzymes, then by eluting fractions of the redox cycle hexameric NADH-glutamate dehydrogenase (GDH) isoenzymes from the polyacrylamide gel to produce non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having different pl values in the electrochemical gradient, wherein the electrochemical gradient comprises acidic, mildly acidic, neutral and mildly alkaline pl values. Further preferred steps in the method include preparing a deamination reaction mixture comprising ribo-NTPs, sodium glutamate, NAD+, and non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having mildly alkaline, neutral, mildly acidic or acidic pl values in the electrochemical gradient, and preparing an amination reaction mixture comprising ribo- - 9 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONNTPs, NH4CI, a- KG, NADH, and non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having acidic, mildly acidic, neutral, or mildly alkaline pl values in the electrochemical gradient, then incubating the deamination reaction mixture and the amination reaction mixture at reaction temperatures varying from 5°C to 20°C. Further preferred steps in the method include isolating and purifying chimerenomic NTinti RNA enzymes from the deamination reaction mixture and the amination reaction mixture, wherein the chimerenomic NTinti RNA enzymes comprise RNA chimere fragments, wherein each RNA chimere fragment comprises at least 150 nucleotides, wherein the RNA chimere fragments degrade RNA specific to the cells, and wherein the chimerenomic NTinti RNA enzymes are free of genetic code-based RNA.

[0037] Additional preferred embodiments of the method may include a step of characterizing the RNA chimere fragments by removing non-functional RNA fragments and terminal ends and sequencing the RNA chimere fragments. Further preferred embodiments may include a step of synthesizing cDNA fragments from the RNA chimere fragments, digesting the cDNA fragments using restriction enzymes, and sequencing the cDNA fragments.

[0038] Additional preferred embodiments disclosed herein include the chimerenomic NTinti RNA enzymes prepared by the method described above. In additional preferred embodiments, the chimerenomic NTinti RNA enzymes are isolated from the deamination reaction mixture or the amination reaction mixture.

[0039] Further preferred embodiments disclosed herein include a method for degrading superfluous or malfunctioning RNAs in a cell, tissue, or subject comprising administering the chimerenomic NTinti RNA enzymes described above to the cell, tissue, or subject.

[0040] Additional preferred embodiments include a pharmaceutical composition comprising a therapeutically effective amount of the chimerenomic NTinti RNA enzymes described above and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer, stabilizer, or mixture thereof.

[0041] Additional preferred embodiments described herein include a method for diagnosis, treatment, or prevention of a disease or disorder that result from superfluous or malfunctioning mRNAs, comprising administering the pharmaceutical composition comprising the chimerenomic NTinti RNA enzymes to a subject. In additional preferred- 10 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONembodiments, the disease is Alzheimer's Disease or Parkinson's Disease. In further preferred embodiments, the disease or disorder is ALS, sickle cell anemia, cancer, diabetes, channel disorders, drug addiction or aging.

[0042] Additional preferred embodiments described herein relate to a method for preparing non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes by extracting NADH-glutamate dehydrogenase (GDH) enzymes from cells using an extraction buffer, wherein the extraction buffer comprises RNase and DNase for the degradation of genetic code-based RNA and DNA, to prepare linearized and monomerized subunits of NADH-glutamate dehydrogenase (GDH) enzymes, followed by using isoelectric focusing to separate and arrange the linearized and monomerized subunits into hexamers of NADH-glutamate dehydrogenase (GDH) enzymes according to electrochemical gradient of pl values, followed by using polyacrylamide gel electrophoresis to concentrate redox cycle hexameric NADH-glutamate dehydrogenase (GDH) enzymes, then by eluting fractions of the redox cycle hexameric NADH-glutamate dehydrogenase (GDH) isoenzymes from the polyacrylamide gel to produce non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having different pl values in the electrochemical gradient, wherein the electrochemical gradient comprises acidic, mildly acidic, neutral and mildly alkaline pl values.

[0043] Additional preferred embodiments relate to a chimerenomic NTinti RNA enzyme, comprising a plurality of RNA chimere fragments, wherein each RNA chimere fragment comprises a plurality of nucleotides, wherein the chimerenomic NTinti RNA enzyme is synthesized using non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes prepared based on enzyme extractions from cells, wherein the chimerenomic NTinti RNA enzymes are free of genetic code-based RNA from the cells.

[0044] Additional preferred embodiments described herein relate to a kit for synthesizing chimerenomic macromolecular RNA enzymes, comprising non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having different chemical gradients, wherein the electrochemical gradients are acidic, mildly acidic, neutral and mildly alkaline, and wherein the non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes were prepared through the method described above. The kit further comprises a deamination reaction mixture comprising ribo-NTPs, sodium glutamate, and NAD+, wherein the deamination reaction mixture is configured - 11 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONto receive the non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having mildly alkaline, neutral, mildly acidic or acidic pl values in the electrochemical gradient and an amination reaction mixture comprising ribo-NTPs, NH4CI, a-KG, and NADH, wherein the amination reaction mixture is configured to receive the nonnatural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having mildly alkaline, neutral, mildly acidic or acidic pl values in the electrochemical gradient.

[0045] Further preferred embodiments described herein relate to a system for synthesizing chimerenomic NTinti RNA enzymes, comprising an isoelectric focusing cell configured to separate and arrange linearized and monomerized subunits of NADH-glutamate dehydrogenase (GDH) enzymes into hexameric NADH-glutamate dehydrogenase (GDH) enzymes according to electrochemical gradient of pl values, wherein the NADH-glutamate dehydrogenase (GDH) enzymes are extracted from cells using an extraction buffer, and wherein the extraction buffer comprises RNase and DNase for the degradation of genetic codebased RNA and DNA. Preferred embodiments of the system further comprise a polyacrylamide gel electrophoresis cell configured to concentrate redox cycle hexameric NADH-glutamate dehydrogenase (GDH) enzymes, a whole gel eluter for eluting fractions of the redox cycle hexameric NADH-glutamate dehydrogenase (GDH) isoenzymes from the polyacrylamide gel electrophoresis cell to produce non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having different pl values in the electrochemical gradient, wherein the electrochemical gradient comprises acidic, mildly acidic, neutral and mildly alkaline pl values, a deamination reaction cell comprising a deamination reaction mixture, wherein the deamination reaction mixture comprises ribo-NTPs, sodium glutamate, NAD+, and non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having mildly alkaline, neutral, mildly acidic or acidic pl values in the electrochemical gradient, an amination reaction cell comprising an amination reaction mixture, wherein the amination reaction mixture comprises ribo-NTPs, NH4CI, a-KG, NADH, and non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having mildly alkaline, neutral, mildly acidic or acidic pl values in the electrochemical gradient, and a characterization tool for analyzing sequenced chimerenomic NTinti RNA enzymes from the deamination reaction mixture and the amination reaction mixture, wherein the chimerenomic NTinti RNA enzymes comprise RNA chimere fragments, wherein each RNA chimere fragment comprises a plurality of nucleotides, wherein the RNA - 12 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONchimere fragments degrade superfluous RNA specific to the cells, and wherein the chimerenomic NTinti RNA enzymes are free of genetic code-based RNA.

[0046] Further aspects of the present invention will become apparent from the following description given by way of example only.EXAMPLES AND RESULTSEXAMPLE 1. SYNTHESIS

[0047] a) Extraction and chemical construction of hexameric NADH-GDH redox cycle isoenzymes.

[0048] Pellet of cultured human cells was homogenized in about 80 mL of 15 mM Tris-HC1 buffer solution, pH 7.5, containing about 20 pL / Lmercaptoethanol, 2 U of DNase 1, and RNase A for 1 to 3 mins at maximum speed. The homogenate was left to stand at room temperature for 30 to 40 min for DNA and RNA to be degraded. Protein precipitated by solid (NH4)2SO4 between 20% and 55% saturation of the homogenate was collected by centrifugation (10,000 x g, 30 min, 5°C). Pellet was resuspended in minimum volume of about 15 mM Tris-HCl pH 7.5 buffer solution, and dialyzed in about 5 L of 15 mM Tris-HCl buffer solution at about pH 8.5: with three changes of the buffer solution over a period of 24 to 36 h. The above protocols eliminated the hexameric structure, linearized and monomerized the subunit polypeptides of the native GDH.

[0049] The dialyzed extract was made up to 50 mL with about 10 mM Tris-HCl buffer pH around 7.5, and subjected to isoelectric focusing (IEF) fractionation. The IEF fractions were dialyzed in 5 L of 10 mM Tris-HCl buffer solution pH around 8.5 also at 5°C; with three changes of the buffer over a period of 24 to 36 h to remove the ampholyte and urea. These IEF protocols created the artificial NADH-GDH redox cycle hexameric isoenzymes with enormous activity to synthesize NTinti RNA enzymes.

[0050] Aliquots of the dialyzed IEF fractions were subjected to Laemmli SDS 12% polyacrylamide gel electrophoresis (PAGE) (100 V, 13 h, 4°C) to remove other proteins. The pair of electrophoresed gels were washed three times with 0.15 mM Tris base at 5 °C to remove the SDS. One gel was thereafter stained with L-glutamate-NAD+-phenazine methosulfate-- 13 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONtetrazolium blue reagent at room temperature. The GDH redox cycle isoenzyme distribution pattern was photo-documented.

[0051] GDH isoenzymes were eluted from the other electrophoresed gel at subzero temperatures using whole gel eluter. The gel fractions were applied for the synthesis of chimerenomic NTinti RNA enzymes (a preferred embodiment of the nongenetic code-based RNA described herein).

[0052] b). Production of chimerenomic NTinti RNA enzymes

[0053] Chimerenomic NTinti RNA enzymes have been produced in the GDH deamination reaction direction as well as in the amination direction. Chigramming was effective in the production of the RNA enzymes.

[0054] b.l). In the deamination reaction direction. The substrate cocktail contained sodium glutamate (50 mg), NAD+, DNase 1 (1 U), actinomycin D (2 pg), RNase inhibitor (10 U), and each ribonucleoside triphosphate dissolved in a minimum volume of 0.1 M Tris-HCl pH 9.3 buffer solution; and placed in a 50 mL GDH chigramming chimmerization tube. The production of the chimerenomic NTinti RNA enzymes was started by mixing some volume of the GDH redox cycle isoenzymes eluted by the whole gel eluter with the substrate cocktail and making up the final reaction volume to 10 mL with 0.1 M Tris-HCl buffer pH 9.3 solution. The reaction tube was then inserted in the GDH chigramming chimmerization cell; the incubation temperature was programmed to swing from 5 °C to 16 °C per 5 min, overnight. The human astrocyte GDH isoenzymes eluted by the whole gel eluter contained about 5 pg protein per mL NTinti RNA enzyme production reaction was stopped by phenol-chloroform extraction of the GDH, followed by ethanol precipitation of the RNA enzymes, pelleted by centrifugation; the RNA pellet air-dried briefly, and dissolved in minimum volume of molecular biology quality water. The solution was stored in -80 °C freezer.

[0055] The chimerenomic NTinti RNA enzyme was submitted to the next generation RNA sequencing, to sequence it and to determine its yield of chimeres in readiness for the studies on their therapeutic applications.

[0056] b.2). In the amination reaction direction: The substrate cocktail contained the four ribo-nucleoside triphosphates, NH4CI (227 mg), a- KG (175 mg), NADH (18 mg), DNase 1 (1 U), actinomycin D (2 pg), RNase inhibitor (10 U), dissolved in a minimum volume of 0.1- 14 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONM Tris-HCl buffer solution pH 8.0, and placed in a 50 mL GDH chigramming chimmerization tube. The production of the chimerenomic NTinti RNA enzymes was started by mixing some volume of the GDH redox cycle isoenzymes eluted by the whole gel eluter with the substrate cocktail and making up the final reaction volume to 25 mL with 0.1 M Tris-HCl buffer pH 8.0 solution. The reaction tube was then inserted in the GDH chigramming chimmerization cell of the chimerenomic pump; the incubation temperature was programmed to swing from 5 °C to 16 °C per 5 min, overnight. NTinti RNA enzyme production was stopped by pH 5.5 phenolchloroform extraction of the GDH, followed by ethanol precipitation of the RNA enzymes, RNA was pelleted by centrifugation; the pellet was air-dried briefly, and dissolved in minimum volume of molecular biology quality water. The solution was stored in -80 °C freezer.

[0057] The chimerenomic NTinti RNA enzyme was then submitted to the next generation RNA sequencing, to sequence it and to determine its yield of chimeres in readiness for the studies on their therapeutic applications.EXAMPLE 2. SYNTHESIS AND CHARACTERIZATION

[0058] Multi-Dimensional Electrophoretic Purification of GDH Hexameric Isoenzymes.

[0059] NADH-Glutamate dehydrogenase (GDH) was extracted from cultured mammalian cells, or from leaves / viable seeds (15 - 30 g) of higher plants. The dialyzed extract was subjected to free solution isoelectric focusing methodology to arrange the GDH hexameric isoenzymes in the gradient of their isoelectric point (pl) values. The isoelectric focusing ampholyte was pl 3 / 10. Ribonuclease A, and deoxyribonuclease 1 were added to the 0.1 M Tris-HCl pH 8 extraction buffer. After isoelectric focusing, the pH values of the IEF fractions were recorded before the fractions were dialyzed to remove the urea and ampholyte.

[0060] Aliquots (100 to 300 pL) of the dialyzed IEF fractions were subjected to native 7.5% polyacrylamide gel (PAG) electrophoresis in duplicate. After the gel electrophoresis, one gel was stained with the phenazine methosulfate-glutamate-NAD+-tetrazolium bromide solution to locate the positions of the GDH isoenzymes. GDH isoenzyme distribution pattern in the gel landscape was photo-documented. Using the stained gel as guide / template on a lightbox, the location of the GDH isoenzymes was excised from the duplicate electrophoresed gel. The GDH isoenzymes were electro-eluted in 0.05 M Tris-HCl solution from the excised- 15 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONpiece of gel using Bio-Rad whole gel eluter at -20°C. The fractions from the whole gel eluter were not combined.

[0061] GDH Chigramming: The Synthesis of Chimerenomic RNA Enzyme

[0062] Synthesis of chimeres was conducted in the amination substrate and deamination substrate solutions in separate tubes of a chigrammer / chimmerization cell. The fractions from whole gel eluter were combined as follows to make 4 groups:Group 1: acidic isoenzymes (pl 5.1) whole gel fractions 3 and 4.Group 2: mildly acidic isoenzymes (pl 6.3) whole gel fractions 5 and 6.Group 3: neutral isoenzymes (pl 7.2) whole gel fractions 7, 8, and 9.Group 4: mildly alkaline isoenzymes (pl 8.5) whole gel fractions 10, and 11.

[0063] For demonstrating the arrays of chimeras chigrammed in the amination direction, the substrate solutions were prepared in 0.1 M Tris-HCl buffer (pH 7.5) containing the four ribo-NTPs (0.6 mM each), CaCh (3.5 mM), NH4CI (0.875 mM), a-ketoglutarate (10.0 mM), NADH (0.225 mM), 5 Units RNase inhibitor, 10 Units of DNase 1, and 5 pg of actinomycin D. The reaction cocktail (0.4 mL) was pipetted into each of four 15 rnL chigrammer tubes on ice bath. The chigrammer tubes were numbered groups 1 to 4 for the GDH isoenzymes. Reaction was started by adding 0.4 mL of whole gel-eluted GDH isoenzymes containing 5 - 11 pg protein per mL to the respective chigrammer tube. The final volume of reaction was adjusted to 1.0 rnL with 0.1 M Tris-HCl buffer solution pH 7.5. Reaction was incubated at 16°C for 60 min in the chimera chigrammer; and stopped by phenolchloroform (pH 5.5) removal of proteins. The chimerenomic RNA enzyme was precipitated with ethanol, pelleted (6000 g, 15 min), the pellet was air-dried to remove phenol and ethanol, then dissolved in minimum volume of molecular biology quality water; and stored at -20°C in preparation for analysis. RNA enzyme yield and quality were verified by photometry and by agarose gel electrophoresis using RNA molecular weight markers as standards. The agarose gel was stained with ethidium bromide solution, and the RNA yield / distribution pattern was photo documented.

[0064] In the deamination direction, the substrate solutions were prepared in 0.1 M Tris-HCl buffer pH 9.0 containing the four ribo-NTPs (0.6 mM each), CaCh (3.5 mM), L-glu - 16 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATION(3.23 pM), NAD+(0.375 pM), 5 Units RNase inhibitor, 10 Units DNase 1, and 5 pg of actinomycin D. The reaction cocktail (0.4 mL) was similarly setup in each of four 15 rnL chigrammer tubes on ice bath. The chigrammer tubes were labeled groups 1 to 4 for the GDH isoenzymes. Reaction was started by adding 0.4 rnL of whole gel-eluted GDH charge isomers containing 5 - 11 pg protein per mL to the respective chigrammer tube. The final volume of reaction in each chigrammer tube was brought to 1.0 rnL with 0.1 M Tris-HCL buffer solution pH 9.0. The purified GDH isoenzymes were same as those used for the amination reaction. Reactions was incubated at 16°C for 60 min in the chimere chigrammer and stopped by phenolchloroform (pH 5.5) removal of the proteins. The chimerenomic RNA enzyme was precipitated with ethanol, then pelleted (6000 g, 15 min), the pellet was air-dried, and dissolved in minimum volume of molecular biology quality water; and stored at -20°C before use. The RNA yield and quality were verified by photometry and by agarose gel electrophoresis using RNA molecular weight markers as standards. The agarose gel was stained with ethidium bromide solution, and the RNA yield / distribution pattern was photo documented.

[0065] Quality Assurance Determinations of the Chimeres

[0066] This was done through conversion of the chimeres to cDNA followed by their restriction enzyme digestion. cDNAs were synthesized with 2 pg of each product chimere synthesized by the whole gel-eluted GDH isoenzymes in the deamination direction, and amination direction, using random hexamer primer. Digestion of the cDNA with taq 1 restriction enzyme;32P-labeled adapter and linker ligations to the restriction fragments; restriction fragment PCR amplification; sequencing gel fractionation to remove excess32P-labeled adapter and32P-labeled NTP were conducted according to the methods of Display Systems Biotech, Vista, CA, USA. The sequencing gel was radio autographed. The resulting images (bands) were scanned and quantified using the Un-Scan-it digitalizing software of Silk Scientific Inc., UT, USA. The band intensities of the chimerenomic RNAs synthesized by the neutral isoenzymes (pl 7.2) in the amination direction were applied as baseline for normalizing and for the calibration of the results.

[0067] Results

[0068] Sequencing gel bands were semi-quantitatively normalized with the bands in one lane as baseline, assigned the value of a unit. The bands represented chimeres chigrammed by the acidic isoenzymes (pl 5.1) in the amination direction (lane A), and deamination direction- 17 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATION(lane E); mildly acidic isoenzymes (pl 6.3) in the amination direction (lane B), and deamination direction (lane F); neutral isoenzymes (pl 7.2) in the amination direction (lane C), and deamination direction (lane G); mildly alkaline isoenzymes (pl 8.0) in the amination direction (lane D), and deamination direction (lane H), used for cDNA synthesis. The cDNAs were digested with taq 1 restriction enzyme, the fragments were amplified by Double Differential PCR method, and the products were fractionated on sequencing polyacrylamide gel. Differential yields existed of product chimeres by GDH Shiff bases according to the pl values of the GDH isoenzymes, and amination versus deamination in the chigrammer. Chimerenomic RNA chimmerized in the amination direction by the acidic, and mildly acidic GDH isoenzymes (lanes A, and B), were semi-quantitatively higher than those synthesized by the same GDH hexameric isoenzymes in the deamination direction. Also, the yields of RNA fragments synthesized by the mildly alkaline GDH isoenzymes (lane H) in the deamination direction were about three folds higher than those synthesized in the amination direction (lane D).

[0069] These observations suggest that the GDH redox cycle consists of two main cycles of unequal activities in the chigramming (synthesis) of chimerenomic RNA; the acidic, mildly acidic, and neutral GDH isoenzymes being very active in the amination direction, whereas the mildly alkaline isoenzymes were more active in the deamination direction. The RNase and DNase that were added to the GDH extraction buffers hydrolyzed all the genetic code-based nucleic acids and assured that the resulting oligonucleotide products were removed during the multi-dimensional electrophoretic purification of GDH hexameric isoenzyme.

[0070] Fractionation on the Sequencing Gel and the Restriction Fragments

[0071] GDH amination reaction (left side) and deamination reaction (right side) were molecularly demonstrated in chemistry, visually in real-time (FIG. 1). The cDNA bands in FIG. 1, lane A were reverse-transcribed from the chimerenomic RNAs chigrammed in the aminating direction by the acidic GDH isoenzymes (pl 5.1); whilst the cDNA bands in FIG. 1, lane E were reverse-transcribed from the chimerenomic RNAs chigrammed in the deaminating direction by the same pl 5.1 GDH isoenzymes. In this molecular chemistry approach, GDH amination was physically separated from the deamination reaction without introduction of any inhibitors into the chigramming reactions.

[0072] The cDNA bands in lane B were reverse-transcribed from the chimerenomic RNAs chigrammed by the mildly acidic GDH isoenzymes (pl 6.3) in the aminating direction;- 18 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONwhilst the bands in lane F were reverse-transcribed from the chimerenomic RNAs chigrammed by same mildly acidic GDH isoenzymes (pl 6.3) in the deaminating direction.

[0073] The cDNA bands in lane C were reverse-transcribed from the chimerenomic RNAs chigrammed by the neutral GDH isoenzymes (pl 7.2) in the aminating direction; whilst the bands in lane G were reverse-transcribed from the chimerenomic RNAs chigrammed by same pl 7.2 neutral GDH isoenzymes in the deaminating direction.

[0074] The cDNA bands in lane D were reverse-transcribed from the chimerenomic RNAs chigrammed by the alkaline GDH isoenzymes (pl 8.5) in the aminating direction; whilst the bands in lane H were reverse-transcribed from the chimerenomic RNAs chigrammed by same pl 8.5 alkaline GDH isoenzymes in the deaminating direction.

[0075] GDH hexameric isoenzymes chigrammed plus-RNA enzyme in the amination direction; but minus-RNA enzyme in the deamination direction. These molecular chemistry models of the opposite chemical differences in chimerenomic RNA primary structure illuminate the hitherto inexplicable phenomena shrouding the reductive amination and the oxidative deamination activities of GDH and are crucially important for understanding the molecular logic of the regulation of metabolism and biological processes in higher organisms. They confirm that the chigramming of chimerenomic RNAs is a cycle of different irreversible chemical reactions driven by NADH / NAD+, and a-KG / L-Glu / NH4+couples rather than a classical reversible oxidation-reduction reaction. The plus / minus chimerenomic RNA chigramming by GDH isoenzymes further confirms the existence of orientation and positionality of the subunit polypeptides in the active hexameric isoenzymes, a structure that only the chimerenomic pump preserved. In the GDH cycle model, the plus-RNA is not reversibly oxidized to minus-RNA. Conversely, the minus-RNA is not reduced to plus-RNA. The chimerenomic circulating pump for the chigramming of minus-RNA and plus-RNA is non-reversible. Therefore, the function of NADH / NAD+, and a-KG / L-Glu / NHC in biology is to establish the redox homoeostasis so that GDH can chimmerize plus-RNA and minus-RNA. In a single sweep of the cycle, GDH isoenzymes chimmerize four folds of the quantities of chimerenomic RNA products of opposite primary structures. The chimerenomic pump is akin to a dual cycling infinitely reciprocating machine complex. This made for thermodynamic efficiency with the spinning out of kilogram quantities of chimerenomic RNA, and economy in the utilization of NADH / NAD+, and of a-KG / L-Glu / NH4+.- 19 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATION

[0076] The reciprocity of the GDH chigramming reaction is clearly demonstrated, internally within the amination reaction domain, and again internally within the deamination reaction domain. The chimerenomic RNA band intensities in lanes A and B were approximately double those of lanes C and D. The converse is the case in the deamination reactions because the band intensities in lanes G and H approximately quadrupled those in lanes E and F. Then furthermore, the total band intensity under the aminating reaction approximately tripled that of the deamination reaction, thereby creating several reciprocal relationships in the maximization of the yield of the product chimerenomic RNAs.

[0077] The plus-RNA, and minus-RNA chigramming is the core of the molecular chemistry of GDH; ensuring that the chimerenomic RNA enzymes are very complicated in primary and secondary structures to match the equally complex structures of the mRNA they degrade. No other template-independent RNA polymerization apparatus can chigramm two types of opposite polarity complicated RNAs simultaneously with such astonishing cyclical chemical repeatability and fidelity. The chigramming of complicated plus-RNA and minus-RNA by GDH is crucial for understanding the molecular reprogramming of metabolic processes consequent upon the degradation of superfluous total RNA by chimerenomic RNA in response to physicochemical changes in the environmental conditions. Hexameric isoenzymes of GDH may henceforth be assayed comprehensively by monitoring the kinetic and thermodynamic transformations of the NADH / NAD+, and / or by the a-KG / L-Glu / NH4+homeostasis at the protein level.

[0078] Effects of the Reaction pH and the pl of the GDH Schiff Base Complex on the Yield Efficiency of Chimerenomic Pump

[0079] The two reactions occurring during the production of chimerenomic RNAs were neatly separated in the radioautographs. The first reaction was the GDH-linked Schiff base formation (GDH-chigramming) which is a base or acid catalyzed reaction that is very important in the synthesis of L-glu by GDH. The second reaction was the GDH-Schiff base dependent polymerization (GDH-chimmerization) of ribo-NTPs (monomers) to give chimerenomic RNA. Because the first reaction requires the GDH-Schiff base to be protonated, the neutral pH of the reaction buffer solution together with the low pl values of the GDH hexameric isoenzymes moderately promoted both the Schiff base formation (chigramming) and moderate yields of the product chimerenomic RNA. Conditions in the deamination reaction were the exact opposite because the moderately higher pH value of the buffer solution made for incomplete protonation -20 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONof the Schiff base thereby enhancing the polymerization (chimmerization) reaction step to achieve the extraordinarily optimal yields of product chimerenomic RNA of higher molecular weight under lane H by the alkaline (pl 8.2) GDH hexameric isoenzymes. The Schiff base reaction mechanism incorporates an initial condensation / addition step that is followed by the polymerization (chimmerization) of activated monomers. The GDH isoenzymes in lanes E, F, and G being mildly acidic were inefficient in the chimmerization reaction step.

[0080] A chimerenomic pump may be considered to consist of free solution IEF cell, polyacrylamide gel electrophoresis cell, whole gel eluter, and chigramming / chimmerization cell seamlessly integrated via electronic automation.EXAMPLE 3. SYNTHESIS AND SEQUENCING

[0081] Extraction and chemical construction of hexameric NADH-GDH redox cycle isoenzymes.

[0082] A pellet of cultured mammalian cells was homogenized in about 80 mL of 15 mM Tris-HCl buffer solution, pH 7.5, containing about 20 pL / Lmercaptoethanol, 2 U of DNase 1, and 1 U of RNase A for 1 to 3 mins at maximum speed. The homogenate was left to stand at room temperature for 30 to 40 min for DNA and RNA to be degraded. Protein was precipitated by solid (NH4)2SO4 between 20% and 55% saturation of the homogenate was collected by centrifugation (10,000 x g, 30 min, 5 °C). Pellet was resuspended in minimum volume of about 15 mM Tris-HCl pH 7.5 buffer solution, and dialyzed in about 5 L of 15 mM Tris-HCl buffer solution at about pH 8.5 : with three changes of the buffer solution over a period of 24 to 36 h. The above protocols eliminated the hexameric structure, linearized and monomerized the subunit polypeptides of the native GDH.

[0083] The dialyzed extract was made up to 50 mL with about 10 mM Tris-HCl buffer pH around 7.5, and subjected to isoelectric focusing (IEF) fractionation. (Osuji GO, Madu WC, Johnson PM 2021, Electrophoretic purification and characterization of human NADH-Glutamate Dehydrogenase redox cycle isoenzymes synthesizing nongenetic code-based RNA enzyme. Advances in Enzyme Research 9: 19-35). The IEF fractions were dialyzed in 5 L of 10 mM Tris-HCl buffer solution pH around 8.5 also at 5°C; with three changes of the buffer over a period of 24 to 36 h to remove the ampholyte and urea. These IEF protocols created the- 21 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONartificial NADH-GDH redox cycle hexameric isoenzymes with activity to synthesize NTinti RNA enzymes.

[0084] Aliquots of the dialyzed IEF fractions were subjected to Laemmli (Lowry OH, Rosenbrough NJ, Farr A, Randall RJ 1951, Protein Measurement with the Folin-Phenol Reagent. Journal of Biological Chemistry, 193: 265-275). SDS 12% polyacrylamide gel electrophoresis (PAGE) (100 V, 13 h, 4°C) was used to remove other proteins. The pair of electrophoresed gels were washed three times with 0.15 mM Tris base at 5°C to remove the SDS. One gel was thereafter stained with L-glutamate-NAD+-phenazine methosulfate-tetrazolium blue reagent at room temperature. The GDH redox cycle isoenzyme distribution pattern was photo-documented.

[0085] GDH isoenzymes were eluted from the other electrophoresed gel at subzero temperatures using whole gel eluter. The gel fractions were used for the synthesis of chimerenomic macromolecular RNA enzymes (nongenetic code-based RNA).

[0086] Production of chimerenomic macromolecular NTinti RNA enzymes

[0087] Chimerenomic NTinti RNA enzymes have been produced in the GDH deamination reaction direction as well as in the amination direction.

[0088] In the deamination reaction direction. The substrate cocktail contained sodium glutamate (50 mg), NAD+, DNase 1 (1 U), actinomycin D (2 pg), RNase inhibitor (10 U), and each ribonucleoside triphosphate dissolved in a minimum volume of 0.1 M Tris-HCl pH 9.3 buffer solution; and placed in a 50 mL GDH chigramming tube. The production of the chimerenomic macromolecular RNA enzymes was started by mixing some volume of the GDH redox cycle isoenzymes eluted by the whole gel eluter with the substrate cocktail and making up the final reaction volume to 10 mL with 0.1 M Tris-HCl buffer pH 9.3 solution. The reaction tube was then inserted in a GDH chigramming cell. GDH chimerization or GDH chigramming is the formation of chemical Schiff base of GDH isoenzymes in response to a new environment leading to new hexameric isoenzyme complexes. This is the initiation process for chigramming. The incubation temperature was programmed to swing from 5 °C to 16 °C per 5 min, overnight. The human astrocyte GDH isoenzymes eluted by the whole gel eluter contained about 5 pg protein per mL. The NTinti RNA enzyme production reaction was stopped by phenol-chloroform extraction of the GDH, followed by ethanol precipitation of the- 22 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONRNA enzymes, pelleted by centrifugation; the RNA pellet air-dried briefly, and dissolved in minimum volume of molecular biology quality water. The solution was stored in -80 °C freezer.

[0089] The chimerenomic NTinti RNA enzyme was submitted to next generation RNA sequencing, to sequence it and to determine its yield of chimeres in readiness for additional studies on their therapeutic applications.

[0090] Representative chimeras of exemplary chimerenomic NTinti RNA enzyme synthesized as described herein were identified as follows by their respective cDNA sequences- SEQ ID NO: 1-6 below were synthesized using hexameric GDH redox cycle isoenzyme complexes from human astrocyte cell extracts at confluency. These hexameric GDH redox cycle isoenzyme complexes produced macromolecular RNA enzymes of approximately 63 million chimeras.CNCCAGGCGGTCAACTTAATGCGTTAGCTGCGCCACTAAAAGCTCAAGGC TTCCAACGGCTAGTTGACATCGTTTACGGCGTGGACTACCAGGGTATCTA ATCCTGTTTGCTCCCCACGCTTTCGCACCTCAGTGTCAGTATTAGTCCAG(SEQ ID NO: 1) CNCTACCATACTCTAGTCAGTCAGTTTTGAATGCAGTTCCCAGGTTGAGCC CGGGGATTTCACATCCAACTTAACAAACCACCTACGCGCGCTTTACGCCC AGTAATTCCGATTAACGCTTGCACCCTCTGTATTACCGCGGCTGCTGGC(SEQ ID NO:2) CNCGGGAACGTATTCACCGCGACATTCTGATTCGCGATTACTAGCGATTCC GACTTCACGCAGTCGAGTTGCAGACTGCGATCCGGACTACGATCGGTTTT ATGGGATTAGCTCCACCTCGCGGCTTGGCAACCCTCTGTACCGACCATT(SEQ ID NO: 3) GAAGGCGACCACCTGGACTAATACTGACACTGAGGTGCGAAAGCGTGGG GAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGTCAA CTAGCCGTTGGAAGCCTTGAGCTTTTAGTGGCGCAGCTAACGCATTAAGTT(SEQ ID NO:4)- 23 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONCTGTGCCAGCAGCCGCGGTAATACAGAGGGTGCAAGCGTTAATCGGAATT ACTGGGCGTAAAGCGCGCGTAGGTGGTTTGTTAAGTTGGATGTGAAATCC CCGGGCTCAACCTGGGAACTGCATTCAAAACTGACTGACTAGAGTATGGT(SEQ ID NO:5)GTGAGATGTTGGGTTAAGTCCCGTAACGAGCGCAACCCTTGTCCTTAGTTA CCAGCACGTAATGGTGGGCACTCTAAGGAGACTGCCGGTGACAAACCGG AGGAAGGTGGGGATGACGTCAAGTCATCATGGCCCTTACGGCCTGGGCTA(SEQ ID NO: 6)

[0091] SEQ ID NO:7-12 below were synthesized using hexameric GDH redox cycle isoenzyme complexes from human astrocyte cell extracts post-confluency. These hexameric GDH redox cycle isoenzyme complexes produced macromolecular RNA enzymes of approximately 71 million chimeres, with each chimera being 150 nucleotides long.NTTCCCTTTTCACGACGGACGTTAGCACCCGCCGTGTGTCTCCCAGGCTCG GCACTTGTCGGTATTAGGAGTTTGCATCGGTTTGGTAAGTCGGGCTGACCC CCTAGCCGAGATCGGAAGAGCACACGTCTGAACTCCAGTCACAGCGCT(SEQ ID NO:7)NGTCAGTCAGTAGTATTTAGCCTTGGAGGATGGTCCCCCCATATTCAGAC AAAGTTTCTCGTGCTCCGTCCTACTCGATTTCATGACTAAGAGATTTTCGC GTACAGGGCTATCACCCACTATGGCCGCACTTTCCAGAGCGTTCCGCTA(SEQ ID NO: 8)NTGGTATCTTCGACCGGCATGAGCTTACGGAGCAAGTCCTTCACCCTCACC GGCGCACCTTCTCCCGAAGTTACGGTGCCATTTTGCCTAGTTCCTTCACCC GAGTTCTCTCAAGCGCCTTGGTATTCTCTACCCAACCACCTGTAGATC(SEQ ID NO:9)CGGCTAGGGGGTCATCCCGACTTACCAAACCGATGCAAACTCCGAATACC TACAAGTGCCGAGCATGGGAGACACACGGCGGGTGCTAACGTCCGTCGTG AAAAGGGAAAAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTGCCTCTA (SEQ ID NO: 10)-24 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONAGCGAACGGGGACTAGCCCTTAAGTGGCTTTGAGATTAGCGGAACGCTCT GGAAAGTGCGGCCATAGTGGGTGATAGCCCTGTACGCGAAAATCTCTTAG TCATGAAATCGAGTAGGACGGAGCACGAGAAACTTTGTCTGAATATGGGG(SEQ ID NO:11) ACAGGTGGTTGGGTAGAGAATACCAAGGCGCTTGAGAGAACTCGGGTGA AGGAACTAGGCAAAATGGCACCGTAACTTCGGGAGAAGGTGCGCCGGTG AGGGTGAAGGACTTGCTCCGTAAGCTCATGCCGGTCGAAGATACCAGAGA TC (SEQ ID NO: 12)EXAMPLE 4. CHARACTERIZATION OF HUMAN ASTROCYTE CELLS AND NADH-GDH

[0092] Human astrocyte cultures have primarily been observed up to the confluence stage, a pivotal moment when cellular proliferation equates to programmed cell death, thus stabilizing cell populations. Traditionally, research has largely overlooked the subsequent attrition (aging) stage when cell dynamics undergo substantial transformations. This study illuminated this critical phase by contrasting human astrocyte cell culture characteristics at confluency (day 9) and, at post-confluency (day 11). At day 9, when control A cells were harvested, the total human astrocyte cell count increased to an impressive 8.71 million cells from initial 0.375 million cells. In stark contrast, at day 11 (2 days after confluency), when control B (aging cells) were harvested, the total human astrocyte cells had markedly declined to 6.79 million cells despite keeping the culture conditions identical. This represented a cell attrition rate of 0.96 million cells per day with a calculated human astrocyte mean lifetime of 9.07 days (218 hours), indicating a shift to survival metabolism, meaning a shift in aging cell molecular-chemistry. Whereas cell count was rapidly declining at this aging stage, cell viability, ironically, improved tremendously from 97.9% to 99.3%; an indication that the more viable the cells are the more likely they survive. These findings underscored marked variations in cell characteristics, including population density, cellular dimensions, morphological profiles, growth kinetics, attrition rates, and biochemical metabolism between human astrocytes in these two states. Utilizing a comprehensive analysis of Glutamate dehydrogenase (GDH) isoenzyme pattern fingerprint, results unveiled profound differences in metabolic processes between the confluency group (control A), with 13 isoenzymes, and cells culled at- 25 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONtwo days post-confluency (control B), with 18 isoenzymes. The data conclusively illustrated that as astrocytes transition from confluency to attrition (aging), they undergo a major metabolic shift that is correlated to NADH-GDH hexameric isoenzyme activity. This study expands the understanding of astrocytic molecular biology and physiology by highlighting the importance of the post-confluency stage, suggesting that cellular aging, characteristics and functionality is driven by molecular changes in NADH-GDH hexameric isoenzyme complex that endows cells the capacity to respond to their internal and external environment irrespective of genes. These results conjure a tectonic shift on approaches to disease diagnosis and treatment, potentially offering new ways to diagnose and cure Alzheimer’s disease, ALS, sickle cell, cancer, diabetes, drug addiction and aging.

[0093] Introduction. The study of human astrocyte cell lines is a vital part of the exploration of the human brain, spanning the fields of neurobiology, neuroscience, and medicine. These glial cells, vital for neural support, synaptic connection, and homeostasis, undergo a significant metamorphosis as they age, transitioning from growth to maturity.

[0094] Astrocytes — once deemed mere bystanders in the complex neural tapestry — now unveil themselves as dynamic players in brain function. Their evolution from youthful precursors to post-confluent aging cells encapsulates a cycle that is intrinsically linked to not just the health of the brain but also its decline. The transition from vitality to senescence is a nuanced narrative, rich with biochemical interactions and molecular cues that orchestrate cellular behavior over time. Yet, the precise timing, nature, and mechanisms governing this transformation have long marveled research scientists, eluding a clear understanding.

[0095] To crack this cerebral code, research embarked on an innovative journey with cultured human astrocyte cell lines. By nurturing precursor astrocyte cells to confluence, this research created an environment conducive to maturation — a critical stage where the cells fully express their potential and functionalities. Two days later, like clockwork, transformation began to unfold as the astrocytes entered a post-confluency state reminiscent of aging process. This pivotal shift heralds a cascade of changes: alterations in morphology, redefinitions of cell signaling pathways, and a reshaping of interactions with neighboring neuronal counterparts.

[0096] Astrocytes: Playing a critical role in the central nervous system, astrocytes form a substantial part of the brain and spinal cord's cellular landscape. These star-shaped glial cells not only account for up to 50% of the cellular volume in certain regions but also revel in- 26 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONtheir abundance, outnumbering neurons by an impressive five to one in some parts of the brain. Varying in shape and function, astrocytes are more than just structural elements; they are dynamic participants in the intricate symphony of neural signaling, playing vital roles in synaptic transmission and maintaining the delicate balance of the central nervous system (CNS).

[0097] Each of the two recognized subtypes — protoplasmic and fibrous astrocytes — contributes to the brain's ecosystem in unique ways. Protoplasmic astrocytes are known for their extensive processes that engage closely with neurons, influencing synapse formation and modulation. Fibrous astrocytes, on the other hand, can primarily be found in the white matter, responsible for supporting myelinated axons and ensuring efficient signal transmission.

[0098] Beyond their structural support and involvement in synaptic function, astrocytes also regulate blood flow to the CNS, acting as key orchestrators in neurovascular coupling. They respond to neuronal activity, ensuring that energy demands are met not just through direct provision of nutrients, but also through complex signaling interactions that are still being unraveled.

[0099] In health and disease alike, astrocytes are at the forefront. They tirelessly secrete a myriad of substances, functioning as reactive agents during injuries and actively participating in the brain’s recovery processes. Their role expands further when considering neurological diseases, as alterations in astrocytic function have been implicated in various disorders, making them a focal point of research for understanding brain pathologies.

[0100] Astrocyte Biology and Pathology: Astrocytes, the remarkable star-shaped glial cells of the central nervous system (CNS), form an intricate tapestry seamlessly woven throughout the neural landscape. These cells are not mere passive bystanders; rather, they play a pivotal role in maintaining homeostasis and providing critical support to neurons. However, when the CNS is confronted with various insults — be it trauma, injury, or disease — astrocytes spring into action in a phenomenon known as reactive astrogliosis. This adaptive response, while essential for repair, has emerged as a hallmark of CNS pathology, indicating a deeper entanglement of astrocytes in both health and disease.

[0101] Recent advancements in neuroscience are shedding light on this intricate process. Research scientists are unraveling the complex functions and mechanisms behind- 27 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONreactive astrogliosis, revealing that it is far from simplistic. It is a graded continuum that hinges not only on the nature of the insult but also on contextual signals that dictate the astrocytic response. No longer considered merely a pathological remnant, reactive astrocytes showcase a versatile molecular arsenal that equips them to either restore homeostasis or contribute to system failures within the CNS.

[0102] Through innovative transgenic mouse models, scientists are meticulously dissecting individual features of astrogliosis and the enigmatic process of glial scar formation. This model-driven exploration is illuminating the intricate roles astrocytes play in specific clinical and pathological contexts, reshaping our understanding of their functional dynamics. Rather than a static or uniform response, the range of changes orchestrated by reactive astrogliosis can transition from reversible adaptations, such as upregulating protective gene expressions and modest cellular hypertrophy while preserving tissue architecture, to enduring transformations that involve permanent scarring and the reorganization of tissue structures.

[0103] Recent research has illuminated critical insights into the intricate process of astrocyte maturation within the cerebral cortex, as often observed in studies involving mice and rodent models. While these findings are tailored to specific species, they shed light on the universal principles governing astrocyte development across mammals. During this esoteric journey of differentiation, various neuroligins — specifically neuroligin 1 (NL1), neuroligin 2 (NL2), and neuroligin 3 (NL3) — have been implicated in orchestrating both astrocyte morphogenesis and synaptogenesis. These proteins serve as vital components, facilitating the connection between astrocytes and neurons, thereby influencing the architecture and functionality of the synaptic landscape.

[0104] Compelling evidence is emerging, emphasizing the dual nature of reactive astrogliosis — it can both thwart and exacerbate CNS disorders. The balance between the loss of essential astrocyte functions and the gain of pathological attributes is a delicate balance underlying many neurological conditions. Research scientists now face the pivotal challenge of fully deciphering this complex interplay within the context of various CNS disorders, paving the way for targeted therapies that could manipulate astrocyte responses for therapeutic gain. The journey to understanding astrocytes, their protective roles, and their detrimental consequences continues to unfold, revealing a world of intricate cellular interactions at the heart of the CNS.- 28 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATION

[0105] Moreover, the understanding of astrogliogenesis extends further when considering the dynamic modifications that astrocytes undergo in response to injury and inflammation. Recent studies have documented a multitude of morphological transformations accompanied by molecular shifts, intricately linked to these external stimuli. Central to this process are an array of transcription factors and signaling proteins, which collectively drive the adaptive responses of astrocytes, enabling them to rearrange their cellular structures and functions in accordance with the demands of their microenvironment.

[0106] Thus, the exploration of astrocyte maturation highlights not only the transformative potential of these glial cells but also underscores the relevance of molecular interactions in mediating their roles during critical periods of neural activity and pathophysiological states. With ongoing advances in our understanding of astrocytic function, future endeavors may unlock new therapeutic avenues through which to harness these versatile cells in the face of neurological injury and disease.

[0107] To date, however, a concrete mechanism elucidating the transition of astrocytes from a confluency to a post-confluency state during growth remains elusive. While extensive studies in mice and rodent models have provided invaluable insights, they inevitably hit a wall when it comes to direct relevance to humans. Evolution has finely tuned human astrocytes, placing them light years ahead of murine species in complexity and functional capacity.

[0108] The complex interplay of molecular factors in astrocyte morphogenesis highlights the intricate narrative unfolding at the cellular level. Key players such as glial fibrillary acidic protein (GFAP), Zinc finger and BTB domain-containing 20 (ZBTB20), Sox9, and NFIA intricately orchestrate the transformation of astrocytes, these pivotal support cells in the central nervous system. Each of these proteins contributes in unique ways, some acting through the repression of the mouse brain-2 (Brn-2) gene to facilitate this metamorphosis.

[0109] Because of this, research scientists are met with the challenge of reconciling these findings from animal models with the more sophisticated human system. Understanding the precise pathway of astrocyte morphogenesis in humans is paramount as it could hold the key to unlocking therapies for a range of neurological disorders.

[0110] Human Astrocytes differs from Rat and Rodent Astrocytes: The landscape of experimental neurology has long relied on the cellular models derived from rats and other- 29 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONrodents. This foundational approach has led to significant insights into neuronal and glial functions. However, as advanced research methods and a deeper understanding of evolution surface, the stark differences between these models and human biology come to light. The human lineage diverged substantially from rodents and primates, ushering in unique brain functionalities that cannot be adequately reflected through these earlier model organisms.

[0111] Emerging studies illuminate the intricate architecture of human astrocytes. These glial cells, crucial for maintaining homeostasis and supporting neuronal function, are notably larger in size and more complex than those of rats and rodents. Research has emphasized that human astrocytes not only surpass rodents in size but also exhibit a remarkable polarization of Glial Fibrillary Acidic Protein (GFAP+). This unique feature allows for processes and intercellular communications that may extend exponentially, up to tenfold in capacity compared to their non-human counterparts.

[0112] GDH Responsible for Cell Metabolic Reprograming: In the intricate world of cellular biology, the ability of cells to regenerate and adapt is not just fascinating, it is essential for understanding various physiological processes and the underlying mechanisms of aging. Among the molecular juggernauts that play a pivotal role in cellular reprogramming, NADH-dependent glutamate dehydrogenase (GDH) stands out. This hexameric enzyme complex emerges as the ultimate gatekeeper of cellular function, deftly regulating biomolecular and physical changes within cells, particularly impacting astrocyte growth and maturation.

[0113] Research has taken a closer look at the remarkable evolution of GDH isoenzymes within human astrocyte cells as they transition from state to state, namely from mature entities to those increasingly marked by the signatures of aging. By isolating and characterizing the distinct alterations in these NADH-GDH isoenzymes, and illustrating the nuanced interplay between enzymatic activity and cellular morphology — a narrative of congruency revealing how changes in biochemical pathways mirror observable shifts in cell structure can become visible, even to the naked eye, after western blot (FIG. 2).

[0114] Legend to FIG. 2: Image comparing the GDH Isoenzyme Fingerprint for Control A (at Confluency) and Control B (at 2 days post Confluency). This unique unprecedented 4 image comparison pattern presented here are the hallmark of the correlation between change in GDH fingerprint and Astrocyte cellular morphologic changes. The first roll shows the GDH hexameric redox cycle isoenzyme distribution pattern as photo-documented-30- 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONfor control A (day 9) and for control B (day 11) after dialyzed IEF fractions were subjected to Laemmli SDS 12% polyacrylamide gel electrophoresis (PAGE) (100 V, 14 h, 4°C) to remove other proteins and nucleic acids. Notice the difference in the GDH isoenzyme fingerprint pattern The second roll shows the electron micrographs for control A (day 9) and control B (day 11) side-by-side. Notice the difference in the micrograph on day 9 showing mature health Astrocyte culture and the micrograph on day 11 showing older and degenerating Astrocyte culture. The post confluency astrocyte cells were more complicated phenotypically than the cells at confluency. Also, the GDH hexameric isoenzyme distribution pattern was more complicated in the post confluency astrocyte cells (Control B) than in the cells at confluency (Control A).

[0115] Examining human astrocyte cells (HACs) provides a robust platform for understanding these processes. Recognizing the relationship between GDH enzyme dynamics and astrocyte morphology, novel insights into cellular aging mechanisms and new avenues for therapeutic interventions in neurological conditions are revealed. Using astrocyte cells as the subject, and the hexameric isoenzymes of NADH-GDH as the pivot enzyme, a comparisonbased research approach hereunder provided evidence that transitioning astrocyte cells from growth, at confluency, to aging cells, at post confluency, correlated to the transitioning of NADH-GDH isoenzymes from a simple binomial to a highly complex distribution pattern that produce novel technologies in pharmacological diagnoses and prevention and therapies for inexplicable neurological disorders and primary clinical infirmities.

[0116] Human astrocyte progenitor lines were acquired from iXcell Biotech, and their protocols were used by Southwest Research Institute (SwRI) to grow the cultures. The experimental phase extended up to 11 days, with conscientious monitoring of cellular developments during this crucial period. Notably cultures were in duplicates, creating Control A and Control B, both seeded with identical cell numbers from the same astrocyte progenitor cells. Control A was meticulously harvested at day 9, precisely at the point of confluency. On the other hand, Control B was harvested at day 11, 2 days post-confluency.

[0117] Free Solution Isoelectric Focusing: The Control A human astrocyte cell culture harvested on day 9 at cell confluency, and the Control B harvested on day 11 at post-confluency were applied for the purification according to the methods of Osuji et al (2021) without any modification. Essentially the pellet of the cells was homogenized in 80 mL of 15 mM Tris-HCl buffer solution, pH 7.5, containing 20 pL / Lmercaptoethanol, DNase 1,- 31 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONand RNase A for 1 min at maximum speed. The homogenate was left to stand at room temperature for 30 min for DNA and RNA to be degraded. Protein precipitated by solid (NH4)2SO4 between 20% and 55% saturation of the homogenate was collected by centrifugation (10,000 x g, 30 min, 5°C). The pellet was resuspended in minimum volume of 15 mM Tris-HCl pH 7.5 buffer solution, and dialyzed in 5 L of 15 mM Tris-HCl buffer solution pH 8.5; with three changes of the buffer solution over a period of 36 h.

[0118] The dialyzed extract was made up to 50 mL with 10 mM Tris-HCl buffer pH 7.5, and subjected to isoelectric focusing fractionation, fractions were dialyzed in 5 L of 10 mM Tris-HCl buffer solution pH 8.5 also at 5 °C; with three changes of the buffer over a period of 36 h to remove the ampholyte and urea.

[0119] Polyacrylamide Gel Electrophoresis: Aliquots (200 to 300 pL) of the dialyzed fractions were subjected to Laemmli SDS 12% polyacrylamide gel electrophoresis (PAGE) (100 V, 14 h, 4°C) to remove other proteins and nucleic acids. Protean II xi electrophoresis cell was used. The electrophoresed gels were washed three times with 0.15 mM Tris base at 5 °C to remove the SDS. Gel was thereafter stained with L-glutamate-NAD+-phenazine methosulfate-tetrazolium blue reagent at room temperature. The GDH hexameric redox cycle isoenzyme distribution pattern was photo-documented. The IEF purification was repeated two or three times to assure reproducibility of the GDH isoenzyme pattern per experimental astrocyte cultured cells.

[0120] GDH Isoenzymes Patterns: This study observed a distinct variation in the isoenzyme patterns of Glutamate dehydrogenase (GDH) between two control groups. Control A, evaluated at day 9, displayed a unique GDH isoenzyme profile that markedly contrasts with the pattern recorded for Control B at day 11. For Control A at day 9, the cell imagery revealed a robust cellular landscape, resonating with the prominent GDH activity, while Control B at day 11 presented a different cellular architecture, correlating with its altered GDH isoenzyme expression. The juxtaposition of isoenzyme patterns alongside visual cellular context allowed for a comprehensive understanding of the metabolic variations at play. The electron micrographic images of the human astrocyte cells at confluency (Control A, day 9) and at post-confluency (Control B, day 11) were the real-life snap shots of the otherwise transient imperceptible morphological transition from one stage of growth to the next. The GDH hexameric isoenzyme distribution patterns showed biochemical changes that triggered the morphological transitions. The post confluency astrocyte cells were more complicated - 32 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONphenotypically than the cells at confluency. Also, the GDH hexameric isoenzyme distribution pattern was more complicated in the post confluency astrocyte cells (Control B) than in the cells at confluency (Control A). There were merely two rows of the hexameric isoenzymes at the confluency growth stage, but there were three rows of the hexameric isoenzymes at the post confluency growth step. It is generally difficult to demonstrate independent visual lines of corroborative evidence in support of biological phenomena, but here the hexameric isoenzymes of GDH have converged with the human astrocyte morphological transition to reveal the function of the enzyme at the molecular level (see Fig. 2).

[0121] GDH is encoded by two nonallelic genes (GHD 1 and GDH 2 ) with GDH 1 encoding the more acidic polypeptides (a) and (a), being heterozygous and codominant; and GDH 2 encoding the less acidic polypeptide (0) being homozygous. The binomial distribution of the three types of polypeptides gives rise to the complex system of hexameric isoenzymes. In the human laryngeal epithelial cells, the GDH was readily resolved to 28 hexameric isoenzymes (Osuji et al., 2021). In the human astrocyte cells, the hexameric GDH isoenzymes numbered about 13 for the Control A but were up to 18 for the Control B judging from the standard statistical binomial distribution pattern. This is evidence for the tissue specificity of the biological function of the enzyme. The differences of the numbers of the hexameric isoenzymes show that GDH responds to the cues of growth and development manifested as the transition from confluency to post confluency. As an aim of this experiment was to define the chemical basis of cellular maturity in human health and disease conditions, the involvement of GDH in the morphological change of human astrocyte cells has interjected far-reaching implications on the practice of molecular cell biology. Changes in the numbers of the hexameric isoenzymes of GDH are caused by chemical reaction. It is an exact chemical event, because no number of triplicate repeats of the cell culture protocols would have altered the GDH fingerprints.

[0122] The results from this study clearly demonstrated the tissue specificity of NADH-GDH isoenzyme fingerprints in human astrocyte cell culture, consistent with findings from human laryngeal cell culture and, indeed, with any cell culture.EXAMPLE 5. APPLICATION TO ALZHEIMER’S DEMENTIA AND PARKINSON’S DISEASE

[0123] Amyloid pathogenesis is a critical process in the development of- 33 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONneurodegenerative diseases, particularly Alzheimer's disease. It begins with the altered cleavage of amyloid precursor protein (APP), an integral protein located on the plasma membrane of neurons. This abnormal processing is primarily mediated by two key enzymes: P-secretases (BACE1) and y-secretases. When APP is cleaved by -secretases, it produces soluble fragments, but the subsequent action of y-secretases is what leads to the formation of amyloid-beta (AP) peptides, specifically Ap40 and Ap42. These monomers are crucial because they have a tendency to oligomerize and aggregate, forming insoluble Ap fibrils that accumulate into senile plaques — a hallmark of Alzheimer's disease. Once formed, Ap oligomers diffuse into synaptic clefts, where they disrupt synaptic signaling. This interference can lead to impaired communication between neurons, contributing to cognitive decline. As the process continues, Ap monomers polymerize into insoluble amyloid fibrils, which further aggregate into larger plaques. The presence of these plaques triggers a cascade of neurodegenerative events. One significant outcome is the activation of kinases, which leads to the hyperphosphorylation of the microtubule-associated protein tau (r). Hyperphosphorylated tau then polymerizes into neurofibrillary tangles (NFTs), another pathological feature of Alzheimer's disease.

[0124] The aggregation of amyloid plaques and neurofibrillary tangles does not occur in isolation. It is accompanied by the recruitment of microglia, the brain's resident immune cells. These microglia become activated in response to the presence of plaques, leading to a local inflammatory response. While this response is initially protective, chronic activation can contribute to neurotoxicity and exacerbate neuronal damage.

[0125] Ap plaques first emerge in specific areas of the brain, notably the basal, temporal, and orbitofrontal neocortex. These regions are crucial for various cognitive functions, including memory, decision-making, and emotional regulation. The early accumulation of plaques in these areas is often linked to the initial cognitive impairments observed in individuals with Alzheimer's disease. As the disease advances, Ap plaques begin to spread throughout the neocortex, affecting additional regions such as the hippocampus, amygdala, and diencephalon. The hippocampus is vital for memory formation and retrieval, and its involvement is closely associated with the memory deficits characteristic of Alzheimer's disease. The basal ganglia, which play a role in movement and coordination, also become affected in later stages. The spread of Ap plaques to these areas can contribute to a range of symptoms, including changes in motor function and behavior.- 34 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATION

[0126] In critical cases of Alzheimer's disease, Af> plaques can be found throughout the mesencephalon (midbrain), lower brain stem and cerebellar cortex. The involvement of these regions indicates a more widespread neurodegenerative process, which can lead to severe cognitive and physical impairments. The mesencephalon is involved in various functions, including vision, hearing, and motor control, while the cerebellar cortex is essential for coordination and balance. To maintain cellular homeostasis, all cells must continually synthesize new proteins. This process is crucial for various cellular functions, including growth, repair, and response to environmental changes.

[0127] At the heart of protein synthesis are ribosomes, also known as polyribosomes, which are specialized complexes made up of ribonucleic acids (RNA) and proteins. Ribosomes play a pivotal role in translating messenger RNA (mRNA) into proteins, a process that involves several key components. Among these, ribosomal RNA (rRNA) and transfer RNA (tRNA) are essential. rRNA forms the structural and functional core of the ribosome, facilitating the binding of mRNA and tRNA during translation. Meanwhile, tRNA serves as the adaptor molecule that brings the appropriate amino acids to the ribosome, matching them to the codons on the mRNA strand. The intricate interplay between these molecules ensures that proteins are synthesized accurately and efficiently, allowing cells to adapt and thrive in their environments. By continuously producing new proteins, cells can maintain their functions and respond to the dynamic nature of their surroundings, ultimately supporting the overall homeostasis of the organism.

[0128] Impairments in ribosome function have been increasingly recognized as a significant factor in the pathology of AD. Research indicates that these dysfunctions are associated with a decreased rate and capacity for protein synthesis, which is critical for maintaining cellular health and function. Specifically, alterations in the levels of ribosomal RNA (rRNA) and transfer RNA (tRNA) have been observed, alongside an increase in RNA oxidation. These changes suggest that disruptions in protein synthesis may contribute to the onset and progression of AD. Among the various components of the ribosome, the malfunction of 28S ribosomes appears to play a particularly significant role. The 28S rRNA is a crucial part of the ribosomal structure, and its impairment can lead to a cascade of effects that compromise the cell's ability to produce essential proteins.

[0129] As protein synthesis is vital for neuronal function and survival, any decline in this process can have profound implications for brain health. As Alzheimer’s disorder - 35 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONprogresses, individuals may face challenges in recognizing loved ones and navigating familiar environments. This gradual decline engenders frustration and helplessness not only for the patient but also for their families, who struggle to cope with the emotional and practical demands of caregiving. Additionally, late-stage Alzheimer’s can severely impair physical functioning, resulting in difficulty with mobility, unable to perform activities of daily living (ADL) and an increased risk of falls. Support systems, including professional aid and community resources, become essential to ensure both the safety and well-being of those affected. The disease progression can be classified into 3 stages: Cognitive Un-impairment (CU), Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD). In the CU stage, individuals may exhibit no apparent clinical symptoms, but there is an underlying pathological process at work. As MCI progresses to AD, the deterioration of cognitive functions becomes evident, with patients beginning to struggle with activities of daily living (ADLs). Importantly, whereas those with MCI maintain their independence and can manage their daily tasks, individuals diagnosed with Alzheimer's disease typically require assistance, marking a significant shift in their capabilities and quality of life.

[0130] The neurodegenerative disease Parkinson’s disease presents with a clinical hallmark of tremor at rest, muscle rigidity and bradykinesia. The loss of dopaminergic neurons in the substantia nigra of the midbrain is a hallmark characteristic of Parkinson’s disease (PD). Dopaminergic neurons in the substantia nigra play a crucial role in the regulation of movement, coordination, and various cognitive functions. The degeneration of these neurons leads to a significant decrease in dopamine levels, which is essential for smooth and controlled muscle movements. Lysosomal dysfunction may also be involved in Parkinson’s disease

[0028] ,

[0131] Recent research has begun to elucidate the interplay between these mechanisms, indicating that mitochondrial dysfunction may exacerbate a-synuclein aggregation, while neuroinflammation can hinder protein clearance. Understanding these interactions is crucial for developing targeted therapeutic strategies. Ongoing studies aim to clarify these relationships and their implications for PD progression and treatment.

[0132] In Parkinson's disease (PD), disruptions in mRNA processing have been linked to the small ribosomal subunit protein uS13. These malfunctions can result in flawed protein synthesis, contributing to neurodegeneration. Research suggests that alterations in the translation machinery may play a crucial role in the progression of PD, like in Alzheimer’s- 36 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONdisease. Understanding these parallels may offer insights into therapeutic strategies targeting ribosomal function.

[0133] The implications of this research are profound, as it not only seeks to provide a cure for AD and PD but also paves the way for a deeper understanding of RNA's role in neurodegenerative diseases.

[0134] Materials and Methods.

[0135] In Vitro Culture of Human Astrocyte Cells: Human astrocyte progenitor lines were acquired from iX Cell Biotech, and their protocols including thawing and seeding, daily media changes, and cell harvesting procedures were used by Southwest Research Institute to grow the cultures. The experimental phase extended up to Day 11, with monitoring of cellular developments. Notably, cultures were established in duplicate, creating Control A and Control B, both starting from identical numbers of the progenitor cells. Control A was harvested on day 9, exactly at the point of confluence. On the other hand, Control B was harvested on day 11, after 2 days of post-confluence.

[0136] Extraction of NADH-Glutamate Dehydrogenase Hexameric Isoenzymes from Human Astrocyte Cells. Free solution isoelectric focusing and PAGE (polyacrylamide gel electrophoretic) concentration of the hexameric isoenzymes were performed as described in examples above. The Control A human astrocyte cells harvested on day 9 at cell confluency, and the Control B harvested on day 11 at post-confluency were applied for the enzyme extraction. The cell pellet was homogenized in 80 mL of 15 mM Tris-HCl buffer solution, pH 7.5, containing 20 pL / Lniercaptoethanol, 2 Units of DNase 1, and 1 Unit of RNase A for 1 min at maximum speed. The homogenate was left to stand at room temperature for 30 min for DNA and RNA to be degraded. Protein precipitated by solid (NH4)2SO4 between 20% and 55% saturation of the homogenate was collected by centrifugation (10,000 x g, 30 min, 5°C). The pellet was resuspended in minimum volume of 15 mM Tris-HCl pH 7.5 buffer solution, and dialyzed in 5 L of 15 mM Tris-HCl buffer solution pH 8.5 with three changes of the buffer solution over a period of 36 h. The dialyzed extract was made up to 50 mL with 10 mM Tris-HCl buffer pH 7.5, and subjected to free solution isoelectric focusing fractionation. IEF fractions were dialyzed in 5 L of 10 mM Tris-HCl buffer solution pH 8.5 also at 5°C with three changes of the buffer over a period of 36 h to remove the ampholyte and urea.- 37 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATION

[0137] Aliquots (100 to 300 pL) of the dialyzed IEF fractions were subjected to Laemmli SDS 12% polyacrylamide gel electrophoresis (PAGE) (100 V, 14 h, 4°C) to remove nucleic acids and other proteins. Protean II xi electrophoresis cell was used. The electrophoresed gels were washed three times with 0.15 mM Tris base at 5°C to remove the SDS. One gel was thereafter stained with L-glutamate-NAD+-phenazine methosulfate-tetrazolium blue reagent at room temperature. The GDH hexameric redox cycle isoenzyme distribution pattern was photo documented. The second electrophoresed gel was applied for the elution of the GDH hexameric isoenzymes contained therein. IEF purification was repeated two or three times to assure reproducibility of the GDH isoenzyme pattern per experimental astrocyte cultured cells.

[0138] Whole Gel Elution of the Hexameric Isoenzymes: The stained polyacrylamide gel (PAG) as template was placed under the unstained PAG on a light box to cut out the section of the unstained PAG containing the GDH hexameric isoenzymes as already described. The GDH isoenzymes were electro-eluted from the excised piece of PAG using Bio-Rad miniwhole gel eluter at subzero temperature. The whole-gel purified GDH isoenzymes contained about 4 pg protein per ml. The protein contents were determined using the Folin-phenol reagent, and with bovine serum albumen as standard. The eluted GDH hexameric isoenzymes (about 6 mL total volume) were not stored but applied immediately for chimerenomic RNA enzyme synthesis in order to maintain the molar relationships between the GDH hexamers and the biological idiosyncrasy of the astrocyte cells used in the extraction of GDH.

[0139] Chimerenomic RNA Enzyme Synthesis: The substrate cocktail has been described above and was prepared by adding the four ribo-NTPs (0.6 mmol each), NH4CI (100 pmol), a- KG (50 pmol), NADH (0.2 pmol), DNase 1 (1 U), actinomycin D (2 pg), and RNase inhibitor (10 U); the final volume was made up to 1 mL with 0.1 M Tris-HCl buffer solution pH 8.0. The reaction was started by adding 1.0 mL of GDH isoenzyme solution, followed by incubation at 16°C overnight in the chilled circulating water bath of chimerenomic pump. RNA synthesis was stopped by phenol -chloroform (pH 5.5) extraction of the GDH. RNA was precipitated with ethanol, air-dried briefly, and dissolved in 40 pL of molecular biology quality water, and stored as 5 pL aliquots at -80 °C. RNA synthesis was carried out in duplicate to verify reproducibility of the yields.

[0140] Chimerenomic NTinti RNA Sequencing: The chimerenomic RNAs were custom sequenced by CD Genomics, New York, USA.- 38 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATION

[0141] Results and Discussion

[0142] Quality of the Cultured Astrocyte Cells at Harvest. The diameter of the astrocyte cells of 15.7 on day 9 at confluency, and 15.8 on day 11 post confluency; cell viability of 97.9% on day 9, and 99.3% on day 11; cell count of 8.71 million on day 9, and 6.79 million on day 11 were evidence that the cell handling protocols and procedure throughout the experimentation agreed with the standards recommended by the American Type Culture Collection. Therefore, the comparative research design that includes a control at cell confluency and a parallel control that extends post confluency are more comprehensive in adducing new results at the molecular level than the statistical triplicating design that lacks any insight into the chemical reactions occurring at the molecular levels.

[0143] GDH Hexameric Isoenzyme Distribution Patterns on Slab of PAG

[0144] In the human astrocyte cells, the hexameric GDH isoenzymes numbered about 13 for the Control A at confluency but were up to 18 for the Control B at 2 days post confluency compared with the standard statistical binomial distribution pattern of the 28 isoenzymes that is skewed to the left. Therefore, Control A astrocyte GDH distribution pattern deviated from that of the standard binomial showing that environmental physicochemical changes occurred also in the Control A astrocyte cell culture, but the physicochemical changes that occurred in the Control B at post confluency were more elaborate and challenging to the cells. These visible differences in the GDH isoenzyme distribution patterns are noteworthy because they will resurface again and again to corroborate the differences in the chimerenomic RNA enzyme sequence complexities that the different GDH isoenzyme patterns synthesized. However, it is not the numbers of the hexameric isoenzymes that determine GDH chemical activities, rather it is the yield of the chimerenomic RNAs they synthesize together with the nucleotide sequence complexities of the chimeres synthesized. The less complicated the chimera RNA sequences are, the less active the GDH hexameric isoenzymes are in the synthesis of complex chimeras.

[0145] GDH is encoded by two nonallelic genes (GHD 1 and GDH 2) with GDH 1 encoding the more acidic polypeptides (a) and (a), being heterozygous and codominant; and GDH 2 encoding the less acidic polypeptide (0) being homozygous. The binomial distribution of the three types of polypeptides gives rise to the complex system of hexameric isoenzymes. In the human laryngeal epithelial cells, the GDH was readily resolved to 28 hexameric isoenzymes. This is evidence for the tissue specificity of the biological function of the enzyme.- 39 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONThe differences of the numbers and distribution patterns of the hexameric isoenzymes show that GDH responds to the cues of growth, development, and aging manifested as the human astrocyte cells transition from confluency to post confluency. As an aim of this experiment was to define the chemical basis of cellular maturity in human health and disease conditions, the involvement of GDH in the morphological change of human astrocyte cells has interjected far-reaching implications on the practice of molecular cell biology. Changes in the numbers of the hexameric isoenzymes of GDH are caused by chemical reaction. It is an exact chemical event as Osuji and Okea unequivocally demonstrated, not by sciences that are beclouded in uncertainties and statistical probabilities because no number of triplicate resets of the cell culture protocols would have altered the GDH fingerprint and patterns.

[0146] GDH is a complex enzyme both in its Schiff base dependent chemical mechanisms and in the 3-D conformations of its subunits in the hexameric isoenzymes. A crystallographic X-ray diffraction study of GDH allostery showed that the binding of NADH kept the GDH catalytic cleft in a closed confirmation, but the binding of ADP behind the NAD+-specific binding domain kept the catalytic cleft open. Binding glutamate to the NAD+-specific domain induced a large conformational change that closed the cleft between the two domains. Similarly, cryo-electron microscopy and molecular dynamic simulation studies on GDH reported that the binding of NADH triggered anticlockwise conformational rearrangements that enhanced the binding of the inhibitor GTP with the consequent inhibition of the deamination activity. Studies on the allostery showed that GDH from higher organisms is a dimer of trimers stacked on top of each other with the crystal lattice of the hexameric GDH isoenzymes having front and back conformations, demonstrating that allosteric regulation plays a crucial role during in vivo catalysis.

[0147] The protonated Schiff base intermediate between the GDH and a-ketoglutarate (a-KG) is predisposed to nucleophilic attack by ammonium ion, ribo-nucleoside triphosphates, saccharides, amino acids, phosphate, K+, sulfate, polypeptides, chitosan, toxic substances (including but not limited to phytochemicals, heavy metal ions, psychotic chemical substances, fungicide, herbicides) (GDH-chimmerization) in the cell. In the active site of GDH hexamers, the protonated and the unprotonated Schiff bases of adjacent subunit polypeptides cooperate to catalyze ribo-nucleoside triphosphate (ribo-NTP) polymerization reaction by orientating the 3’ nucleotide residue at the growing end of the RNA, and the incoming ribo-NTP, in juxtaposition to permit nucleotide bond formation to occur. The aggregate GDH hexameric isoenzymes of-40 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONany tissues have different pl (isoelectric point) values ranging from pl ~4 to 9.5. So, in any environmental conditions, only some of the isoenzymes will be at neutral pl value. Schiff base complex formation is more / less catalyzed by a physicochemical cooperation between the protonated and the unprotonated adjacent hexameric isoenzymes.

[0148] When there is physicochemical change in the environmental conditions, the nucleophiles that attack the Schiff base complex are not only ribo-NTPs; they lead to the formation of dead-end complexes that inactivate GDH. The inactivated GDH polypeptides are degraded by proteases. Thus, a new GDH isoenzyme population pattern arises in the cells, tissues, and the whole organism whenever there is a physicochemical change in the environmental conditions as illustrated by the transition from confluency to post-confluency aging processes. The prevalent GDH isoenzymes then spontaneously synthesize a new set of chimerenomic RNA enzyme, which immediately degrade and wipe-out pre-existing malfunctioning, mutated, superfluous mRNA, transfer RNAs, rRNAs etc. that the cells and tissues no longer need for healthy metabolism and biological programs of survival; and they unleash a new biological order that is in equilibrium with the new environment, for the continued longevity of the organism. The fundamental function of NADH-GDH is therefore to convert the physicochemical environmental changes into the high molecular weight RNA primary structure. The conversion of the environment-wide changes of cells, tissues, whole organisms to the nucleotide sequences of chimerenomic RNA enzymes is of similar biological importance and consequence as the conversion of the genetic information in total RNA (mRNAs, rRNAs, transfer RNAs) to give the amino acid sequences of proteins. Environmental conditions can now be analyzed and described as specific RNA databases (Chigramming) different from gene bank genomics. This is a novel translational understanding of GDH molecular chemistry that holds the potential for groundbreaking innovations.

[0149] The inactivated dead-end complexes of GDH have been immunochemically demonstrated. The identification of GDH dead-end complexes is live evidence that GDH is the enzyme that synthesizes chimerenomic RNAs (chimeres and NTintis), and that GDH-chimmerization and chigramming are studies in chemical reaction mechanisms. This organic chemistry mechanism, being template independent, spontaneously synthesizes giga quantities of chimerenomic RNA enzymes which then degrade homologous total RNA (mRNA, rRNA, transfer RNA) thereby leading to the reprogramming and repositioning of metabolic processes- 41 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONand providing potential therapies for neurodegenerative health disorders Alzheimer's and Parkinson's diseases etc.

[0150] Chimerenomic RNA Sequencies

[0151] The chimerenomic NTinti RNA enzymes that were synthesized by the GDH hexameric isoenzymes of the Control A astrocyte cells at confluency included a total of 63,000,000 chimerenomic RNA enzymes, each enzyme being about 150 nucleotides long, and was saved in a two data files.

[0152] The chimerenomic RNA enzyme that was synthesized by the GDH hexameric isoenzymes of the Control B astrocyte cells at post confluency include a total of 71,000,000 chimerenomic RNA enzymes, each enzyme being about 150 nucleotides long, and was saved in two data files.

[0153] The human brain transcriptome contains about 32,802 transcripts, each being about 2,770 nucleotides long. The above statistics, which now permit a comparison of the size of the human transcriptome with the size of the human Control astrocyte chimerenomic RNA enzymes shows that the transcriptome is merely about 1% the size of the RNA enzymes. Herein lies the ability of chimerenomic RNA enzyme activity in vivo to spontaneously degrade all mutated, malfunctional, superfluous total RNA (mRNA, tRNA, rRNA, micro-RNA etc.), to reset their abundances, and to reprogram biological processes in the cells, tissues, and whole organism.

[0154] AAPCR functional chimerenomic bioinformatics analysis tool applied to Alzheimer’s and Parkinson’s disorders: The functional chimerenomic bioinformatics analysis tool was developed also for the analyses of the degradation of superfluous / dysfunctional mRNAs, rRNAs, transfer RNAs etc. by chimerenomic RNA enzymes and total RNA (mRNA, rRNA, tRNA etc.) sequences. The Chimerenomic sciences research approach permitted simultaneous studies on the astrocyte mRNAs encoding many dysfunctional / mutated proteins of the neurodegenerative disease pathways.

[0155] mRNAs encoding malfunctional proteins of Alzheimer’s disease pathway: Using the chimerenomic analysis tool and the data files containing the sequences of the RNA enzymes at confluency as subjects, and the mRNAs encoding the Alzheimer's disease-related Chain 5 protein in the 28S ribosome, GenBank Sequence identification - 42 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONnumber: 8QFD_5; that of the amyloid beta precursor protein: NCBI Reference sequence NM_001385253.1; that of beta-secretase: GenBank Accession number AF201468; and that of a-synuclein: Accession number P37840-1 as queries produced mRNA degradation matches with all the 63,340,502 chimerenomic RNA enzymes that were synthesized by the GDH hexameric isoenzymes of the Control A human astrocyte cells at confluency.

[0156] Using the chimerenomic analysis tool and the data files containing the sequences of the RNA enzymes at post-confluency as subjects, and the mRNAs encoding the Alzheimer's disease-related Chain 5 protein in the 28S ribosome, GenBank Sequence identification number: 8QFD_5; that of the amyloid beta precursor protein: NCBI Reference sequence NM_001385253.1; that of beta-secretase: GenBank Accession number AF201468 : that of a-synuclein: Accession number P37840-1 as queries produced mRNA degradation matches with all the 71,068,404 chimerenomic RNA enzymes that were synthesized by the GDH hexameric isoenzymes of the Control B human astrocyte cells at post confluency.

[0157] These spectacular increases in the numbers of age-related mRNA degradation homologies from confluency to post confluency begin to illuminate as never before, the chemical reactions occurring deep in the molecular levels of Alzheimer’s disorder during the astrocyte aging processes.

[0158] mRNAs encoding malfunctional proteins of Parkinson’s disease pathway:

[0159] Using the chimerenomic analysis tool and the data files containing the sequences of the RNA enzymes at confluency as subjects, and the mRNA encoding the Parkinson’s disease-related small ribosomal subunit protein uS 13, GenBank Sequence ID: NP_072045.1 as query revealed that the malfunctional mRNA was degraded by each of the 63,340,502 chimerenomic RNA enzymes that were synthesized by the GDH hexameric isoenzymes of the Control A human astrocyte cells at confluency.

[0160] Using the chimerenomic analysis tool and the data files containing the sequences of the RNA enzymes at post-confluency as subjects, and the malfunctional mRNA encoding the Parkinson’s disease-related small ribosomal subunit protein uS13, GenBank Sequence ID: NP_072045.1 as query revealed that the malfunctional mRNA was degraded by each of the 71,068,404 chimerenomic RNA enzymes that were synthesized by the GDH hexameric isoenzymes of the Control B human astrocyte cells at post-confluency.- 43 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATION

[0161] These analysis tool results mean that post confluency compared with confluency human astrocyte GDH hexameric isoenzymes synthesized 7,727,899 more chimerenomic RNA enzymes with activities that spontaneously degraded more of the malfunctional mRNAs in Alzheimer’s and Parkinson’s disorders thus enhancing the reversals from the disorders. GenBank search engines did not possess the RNA data sets to reveal the mechanisms in molecular chemistry by which chimerenomic RNA enzymes degraded superfluous mRNAs, thereby confirming that chimerenomics is a new science.REFERENCESThe following documents are incorporated by referenced herein.Okea RN, Osuji GO (2024). Transformation from growth to aging in human astrocytes cell culture: The role of NADH-glutamate dehydrogenase isoenzymes. JAAPCR vol. 1: Issue 2.Okea RN, Osuji GO (2025). New treatment for Alzheimer’s dementia and Parkinson’s disease ready for clinical trial: The chimerenomic RNA enzyme. JAAPCR vol. 2: issue 3.Osuji GO, Okea RN (2024). Environment-wide reprogramming of total RNA abundance and metabolic processes by Glutamate dehydrogenase- synthesized RNA enzyme: Terminologies for the New RNAs. JAAPCR vol. 1: Issue 2Osuji GO, OkeaRN (2024). The Chimerenomic Pump: Large-Scale Production of Glutamate Dehydrogenase-Synthesized RNAs. JAAPCR vol. 1: Issue 2Osuji GO, Madu WC, Johnson PM (2021). Electrophoretic purification and characterization of human NADH- Glutamate Dehydrogenase redox cycle isoenzymes synthesizing nongenetic code-based RNA enzyme. Advances in Enzyme Research 9: 19-35.Osuji GO, Madu WC, Johnson PM (2019); Total RNA Degradation in Vitro and in Vivo by Glutamate Dehydrogenase-Synthesized RNA Enzyme: Biotechnological Applications. Advances in Bioscience and Biotechnology > Vol.10 No.4, April 2019Osuji GO, Konan J, M’Mbijjewe G (2004). RNA synthetic activity of glutamate dehydrogenase. Applied Biochemistry and Biotechnology 119: 209-228.- 44 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONOsuji GO, Braithwaite C, Fordjour K, Madu WC, Beyene A, Roberts PS, Wright V (2003).Purification of glutamate dehydrogenase isoenzymes and characterization of their substrate specificities. Preparative Biochemistry & Biotechnology 33: 13-28.Mighani M (2020). Schiff Base polymers synthesis and characterization. Journal of Polymer Research. 27 (168): 1-18.Silva PJ. (2020). New insights into the mechanism of Schiff base synthesis from aromatic amines in the absence of acid catalyst or polar solvents. PeerJ. Organic Chemistry 2:e4 DOI 6.7717 / peerj-ochem.4Xavier A, Srividhya N (2014). Synthesis and study of Schiff base ligands. IOSR J. Applied Chemistry 7: 6-15. 2014.Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. (2019). Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019 Jul 19;14:5541-5554. doi: 10.2147 / IJN.S200490. PMID: 31410002; PMCID: PMC6650620Noor A, Zafar S, Zerr I. (2021). Neurodegenerative Proteinopathies in the Proteoform Spectrum-Tools and Challenges. Int J Mol Sci. 2021 Jan 22;22(3):1085. doi: 10.3390 / ijms22031085. PMID: 33499319; PMCID: PMC7865347Lowry OH, Rosenbrough NJ, Farr A, Randall RJ (1951) Protein Measurement with the Folin- Phenol Reagent. Journal of Biological Chemistry, 193: 265-275.Cammaerts, D. and Jacobs, M. (1983) A Study of the Polymorphism and the Genetic Control of the Glutamate Dehydrogenase in Arabidopsis Thaliana. Plant Science Letters, 31, 65-73. https: / / doi.org / 10.1016 / 0304-421 l(83)90130-X.- 45 - 49424466

Claims

Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONWHAT IS CLAIMED IS:

1. A method for synthesizing chimerenomic NTinti RNA enzymes, comprising:preparing non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes through a method comprising the steps of:extracting NADH-glutamate dehydrogenase (GDH) enzymes from cells using an extraction buffer, wherein the extraction buffer comprises RNase and DNase for the degradation of genetic code-based RNA and DNA, to prepare linearized and monomerized subunits of NADH-glutamate dehydrogenase (GDH) enzymes;using isoelectric focusing to separate and arrange the linearized and monomerized subunits into hexamers of NADH-glutamate dehydrogenase (GDH) enzymes according to electrochemical gradient of pl values;using polyacrylamide gel electrophoresis to concentrate redox cycle hexameric NADH-glutamate dehydrogenase (GDH) enzymes; eluting fractions of the redox cycle hexameric NADH-glutamate dehydrogenase (GDH) isoenzymes from the polyacrylamide gel to produce non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having different pl values in the electrochemical gradient, wherein the electrochemical gradient comprises acidic, mildly acidic, neutral and mildly alkaline pl values;preparing a deamination reaction mixture comprising ribo-NTPs, sodium glutamate, NAD+, and non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having mildly alkaline, neutral, mildly acidic or acidic pl values in the electrochemical gradient;preparing an amination reaction mixture comprising ribo-NTPs, NH4CI, a- KG,-46 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONNADH, and non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having acidic, mildly acidic, neutral, or mildly alkaline pl values in the electrochemical gradient; incubating the deamination reaction mixture and the amination reaction mixture at reaction temperatures varying from 5 °C to 20°C;isolating and purifying chimerenomic NTinti RNA enzymes from the deamination reaction mixture and the amination reaction mixture, wherein the chimerenomic NTinti RNA enzymes comprise RNA chimere fragments, wherein each RNA chimere fragment comprises at least 150 nucleotides, wherein the RNA chimere fragments degrade RNA specific to the cells, and wherein the chimerenomic NTinti RNA enzymes are free of genetic code-based RNA.

2. The chimerenomic NTinti RNA enzymes prepared by the method of claim 1.

3. The chimerenomic NTinti RNA enzymes prepared by the method of claim 1, wherein the chimerenomic NTinti RNA enzymes are isolated from the deamination reaction mixture.

4. The chimerenomic NTinti RNA enzymes prepared by the method of claim 1 , wherein the chimerenomic NTinti RNA enzymes are isolated from the amination reaction mixture.

5. A method for degrading superfluous or malfunctioning RNAs in a cell, tissue, or subject comprising administering the chimerenomic NTinti RNA enzymes of claim 2 to the cell, tissue, or subject.

6. A pharmaceutical composition comprising a therapeutically effective amount of the chimerenomic NTinti RNA enzymes of claim 2 and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer, stabilizer, or mixture thereof.

7. A method for diagnosis, treatment, or prevention of a disease or disorder that result from superfluous or malfunctioning mRNAs, comprising administering the- 47 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONpharmaceutical composition of claim 6 to a subject.

8. The method of claim 7, wherein the disease is Alzheimer's Disease or Parkinson's Disease.

9. The method of claim 7, wherein the disease or disorder is ALS, sickle cell anemia, cancer, diabetes, channel disorders, drug addiction or aging.

10. The method of claim 1, further comprising characterizing the RNA chimere fragments by removing non-functional RNA fragments and terminal ends and sequencing the RNA chimere fragments.

11. The method of claim 1 , further comprising synthesizing cDNA fragments from the RNA chimere fragments, digesting the cDNA fragments using restriction enzymes, and sequencing the cDNA fragments.

12. A method for preparing non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes comprising:extracting NADH-glutamate dehydrogenase (GDH) enzymes from cells using an extraction buffer, wherein the extraction buffer comprises RNase and DNase for the degradation of genetic code-based RNA and DNA, to prepare linearized and monomerized subunits of NADH-glutamate dehydrogenase (GDH) enzymes;using isoelectric focusing to separate and arrange the linearized and monomerized subunits into hexamers of NADH-glutamate dehydrogenase (GDH) enzymes according to electrochemical gradient of pl values;using polyacrylamide gel electrophoresis to concentrate redox cycle hexameric NADH-glutamate dehydrogenase (GDH) enzymes;eluting fractions of the redox cycle hexameric NADH-glutamate dehydrogenase (GDH) isoenzymes from the polyacrylamide gel to produce non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having different pl values in the electrochemical gradient, wherein the - 48 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONelectrochemical gradient comprises acidic, mildly acidic, neutral and mildly alkaline pl values.

13. A chimerenomic NTinti RNA enzyme, comprising:a plurality of RNA chimere fragments, wherein each RNA chimere fragment comprises a plurality of nucleotides, wherein the chimerenomic NTinti RNA enzyme is synthesized using non-natural hexameric NADH- glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes prepared based on enzyme extractions from cells, wherein the chimerenomic NTinti RNA enzymes are free of genetic code-based RNA from the cells.

14. A kit for synthesizing chimerenomic macromolecular RNA enzymes, comprising:non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having different chemical gradients, wherein the electrochemical gradients are acidic, mildly acidic, neutral and mildly alkaline, and wherein the non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes were prepared through a method comprising the steps of:extracting NADH-glutamate dehydrogenase (GDH) enzymes from cells using an extraction buffer, wherein the extraction buffer comprises RNase and DNase for the degradation of genetic code base RNA and DNA, to prepare linearized and monomerized subunits of NADH-glutamate dehydrogenase (GDH) enzymes, using isoelectric focusing to separate and arrange the linearized and monomerized subunits of NADH-glutamate dehydrogenase (GDH) enzymes according to electrochemical gradient of pl values,using polyacrylamide gel electrophoresis to concentrate redox cycle hexameric NADH-glutamate dehydrogenase (GDH) enzymes, and- 49 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONeluting fractions of the redox cycle hexameric NADH-glutamate dehydrogenase (GDH) enzymes from the polyacrylamide gel to produce non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having different pl values in the electrochemical gradient, wherein the electrochemical gradient comprises acidic, mildly acidic, neutral and mildly alkaline pl values;a deamination reaction mixture comprising ribo-NTPs, sodium glutamate, and NAD+, wherein the deamination reaction mixture is configured to receive the non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having mildly alkaline, neutral, mildly acidic or acidic pl values in the electrochemical gradient; andan amination reaction mixture comprising ribo-NTPs, NH4CI, a- KG, and NADH, wherein the amination reaction mixture is configured to receive the non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having mildly alkaline, neutral, mildly acidic or acidic pl values in the electrochemical gradient.

15. A system for synthesizing chimerenomic NTinti RNA enzymes, comprising:an isoelectric focusing cell configured to separate and arrange linearized and monomerized subunits of NADH-glutamate dehydrogenase (GDH) enzymes into hexameric NADH-glutamate dehydrogenase (GDH) enzymes according to electrochemical gradient of pl values, wherein the NADH-glutamate dehydrogenase (GDH) enzymes are extracted from cells using an extraction buffer, and wherein the extraction buffer comprises RNase and DNase for the degradation of genetic code-based RNA and DNA;a polyacrylamide gel electrophoresis cell configured to concentrate redox cycle hexameric NADH-glutamate dehydrogenase (GDH) enzymes;- 50 - 49424466Attorney Docket No.: 170364.00003 PCT PATENT APPLICATIONa whole gel eluter for eluting fractions of the redox cycle hexameric NADH-glutamate dehydrogenase (GDH) isoenzymes from the polyacrylamide gel electrophoresis cell to produce non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having different pl values in the electrochemical gradient, wherein the electrochemical gradient comprises acidic, mildly acidic, neutral and mildly alkaline pl values;a deamination reaction cell comprising a deamination reaction mixture, wherein the deamination reaction mixture comprises ribo-NTPs, sodium glutamate, NAD+, and non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having mildly alkaline, neutral, mildly acidic or acidic pl values in the electrochemical gradient;an amination reaction cell comprising an amination reaction mixture, wherein the amination reaction mixture comprises ribo-NTPs, NH4CI, a- KG, NADH, and non-natural hexameric NADH-glutamate dehydrogenase (GDH) redox cycle isoenzyme complexes having mildly alkaline, neutral, mildly acidic or acidic pl values in the electrochemical gradient; anda characterization tool for analyzing sequenced chimerenomic NTinti RNA enzymes from the deamination reaction mixture and the amination reaction mixture, wherein the chimerenomic NTinti RNA enzymes comprise RNA chimere fragments, wherein each RNA chimere fragment comprises a plurality of nucleotides, wherein the RNA chimere fragments degrade superfluous RNA specific to the cells, and wherein the chimerenomic NTinti RNA enzymes are free of genetic code-based RNA.- 51 - 49424466